Cover
Cover | 6 Months Ended |
Jun. 30, 2021 | |
Entity Addresses [Line Items] | |
Document Type | S-1 |
Amendment Flag | false |
Entity Registrant Name | NEWHYDROGEN, INC. |
Entity Central Index Key | 0001371128 |
Entity Tax Identification Number | 20-4754291 |
Entity Incorporation, State or Country Code | NV |
Entity Address, Address Line One | Primary Standard Industrial Classification Code Number |
Entity Address, Address Line Two | 27936 Lost Canyon Road |
Entity Address, Address Line Three | Suite 202 |
Entity Address, City or Town | Santa Clarita |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 91387 |
City Area Code | (661) |
Local Phone Number | 251-0001 |
Entity Filer Category | Non-accelerated Filer |
Entity Small Business | true |
Entity Emerging Growth Company | false |
Business Contact [Member] | |
Entity Addresses [Line Items] | |
Entity Address, Address Line One | David Lee |
Entity Address, Address Line Two | 27936 Lost Canyon Road |
Entity Address, Address Line Three | Suite 202 |
Entity Address, City or Town | Santa Clarita |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 91387 |
City Area Code | (661) |
Local Phone Number | 251-0001 |
Condensed Balance Sheet
Condensed Balance Sheet - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
CURRENT ASSETS | |||
Cash | $ 7,569,822 | $ 63,496 | $ 61,794 |
Prepaid expenses | 286,207 | 55,435 | 29,956 |
TOTAL CURRENT ASSETS | 7,856,029 | 118,931 | 91,750 |
PROPERTY AND EQUIPMENT | |||
Machinery and equipment | 37,225 | 37,225 | 37,225 |
Less accumulated depreciation | (32,695) | (32,023) | (30,681) |
NET PROPERTY AND EQUIPMENT | 4,530 | 5,202 | 6,544 |
OTHER ASSETS | |||
Patents, net of amortization of $15,112 and $12,090, respectively | 28,713 | 30,224 | 33,246 |
Deposit | 770 | 770 | 770 |
TOTAL OTHER ASSETS | 29,483 | 30,994 | 34,016 |
TOTAL ASSETS | 7,890,042 | 155,127 | 132,310 |
CURRENT LIABILITIES | |||
Accounts payable | 530 | 58 | |
Accrued expenses | 9,647 | 991,716 | 830,425 |
Derivative liability | 73,395 | 148,590,100 | 8,919,202 |
Convertible promissory notes net of debt discount of $219,850 and $254,896, respectively | 100,111 | 1,069,974 | 390,987 |
TOTAL CURRENT LIABILITIES | 183,683 | 150,651,790 | 10,140,672 |
LONG TERM LIABILITIES | |||
Convertible promissory notes net of debt discount of $56,135 and $801, respectively | 1,418,225 | 2,207,349 | |
TOTAL LONG TERM LIABILITIES | 1,418,225 | 2,207,349 | |
TOTAL LIABILITIES | 183,683 | 152,070,015 | 12,348,021 |
SHAREHOLDERS’ DEFICIT | |||
Preferred stock, $0.0001 par value; 10,000,000 authorized shares, none issued and outstanding | 3 | ||
Common stock, $0.0001 par value; 3,000,000,000 authorized shares 456,198,529 and 133,912,520 shares issued and outstanding, respectively | 68,549 | 45,620 | 13,391 |
Preferred treasury stock, 1000 and 0 shares outstanding, respectively | |||
Additional paid in capital | 131,582,079 | 13,114,993 | 12,301,739 |
Accumulated deficit | (123,944,272) | (165,075,501) | (24,530,841) |
TOTAL SHAREHOLDERS’ DECIFIT | 7,706,359 | (151,914,888) | (12,215,711) |
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT | $ 7,890,042 | $ 155,127 | $ 132,310 |
Condensed Balance Sheet (Parent
Condensed Balance Sheet (Parenthetical) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Patents, net of amortization | $ 16,623 | $ 15,112 | $ 12,090 |
Convertible promissory notes net of debt discount, current | 6,889 | 219,850 | 254,896 |
Convertible promissory notes net of debt discount, non current | $ 0 | $ 56,135 | $ 801 |
Preferred stock par value | $ 0.0001 | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 10,000,000 | 10,000,000 | 10,000,000 |
Preferred stock, shares issued | 0 | 0 | |
Preferred stock, shares outstanding | 0 | 0 | |
Common stock par value | $ 0.0001 | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 3,000,000,000 | 3,000,000,000 | 3,000,000,000 |
Common stock, shares issued | 685,496,051 | 456,198,529 | 133,912,520 |
Common stock, shares outstanding | 685,496,051 | 456,198,529 | 133,912,520 |
Treasury stock, shares outstanding | 0 | 1,000 | 0 |
Series C Preferred Stock [Member] | |||
Preferred stock, shares issued | 34,461 | 34,461 | |
Preferred stock, shares outstanding | 34,461 | 34,461 |
Condensed Statements of Operati
Condensed Statements of Operations - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | Dec. 31, 2019 | |
Income Statement [Abstract] | ||||||
REVENUE | ||||||
OPERATING EXPENSES | ||||||
General and administrative expenses | 3,637,312 | 100,240 | 18,438,830 | 219,059 | 447,665 | 428,668 |
Research and development | 251,776 | 40,212 | 508,440 | 83,832 | 177,722 | 264,687 |
Depreciation and amortization | 1,091 | 1,091 | 2,182 | 2,182 | 4,365 | 6,890 |
TOTAL OPERATING EXPENSES | 3,890,179 | 141,543 | 18,949,452 | 305,073 | 629,752 | 700,245 |
LOSS FROM OPERATIONS BEFORE OTHER INCOME (EXPENSES) | (3,890,179) | (141,543) | (18,949,452) | (305,073) | (629,752) | (700,245) |
OTHER INCOME/(EXPENSES) | ||||||
Interest income | 919 | 5 | 1,285 | 12 | 75 | 36 |
Gain on settlement of debt and derivative | 96,666,293 | |||||
Gain (Loss) on change in derivative liability | 250,293 | 6,507,665 | (30,039,479) | (169,011) | (139,038,754) | 5,777,348 |
Interest expense | (15,977) | (231,874) | (563,914) | (457,187) | (876,229) | (954,774) |
TOTAL OTHER INCOME (EXPENSES) | 235,235 | 6,275,796 | 66,064,185 | (626,186) | (139,914,908) | 4,822,610 |
NET INCOME (LOSS) | $ (3,654,944) | $ 6,134,253 | $ 47,114,733 | $ (931,259) | $ (140,544,660) | $ 4,122,365 |
BASIC EARNINGS (LOSS) PER SHARE | $ (0.01) | $ 0.03 | $ 0.18 | $ (0.01) | $ (0.50) | $ 0.04 |
DILUTED EARNING (LOSS) PER SHARE | $ (0.01) | $ 0 | $ 0.06 | $ (0.01) | $ (0.50) | $ 0.01 |
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING | ||||||
BASIC | 659,726,820 | 223,425,846 | 267,786,651 | 184,830,379 | 280,952,034 | 92,022,751 |
DILUTED | 659,726,820 | 2,124,796,718 | 740,069,136 | 184,830,379 | 280,952,034 | 679,815,020 |
Condensed Statement of Sharehol
Condensed Statement of Shareholders' Deficit - USD ($) | Preferred Stock [Member] | Other Additional Capital [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Beginning balance, value at Dec. 31, 2018 | $ 6,064 | $ 11,646,932 | $ (28,653,206) | $ (17,000,210) | ||
Beginning Balance, shares at Dec. 31, 2018 | 60,639,308 | |||||
Issuance of preferred shares for services | 20,000 | 20,000 | ||||
Issuance of preferred shares for services (in Shares) | 1,000 | |||||
Redemption of preferred shares | (20,000) | (20,000) | ||||
Redemption of preferred shares (in Shares) | (1,000) | |||||
Issuance of common shares for converted promissory notes and accrued interest | $ 7,327 | 654,807 | 662,134 | |||
Issuance of common shares for converted promissory notes and accrued interest (in Shares) | 73,273,212 | |||||
Net Income | 4,122,365 | 4,122,365 | ||||
Ending balance, value at Dec. 31, 2019 | $ 13,391 | 12,301,739 | (24,530,841) | (12,215,711) | ||
Ending balance, shares at Dec. 31, 2019 | 133,912,520 | |||||
Issuance of common shares for converted promissory notes and accrued interest | $ 14,882 | 398,852 | 413,734 | |||
Issuance of common shares for converted promissory notes and accrued interest, shares | 148,822,552 | |||||
Net Income | (931,259) | (931,259) | ||||
Ending balance, value at Jun. 30, 2020 | $ 28,273 | 12,700,591 | (25,462,100) | (12,733,236) | ||
Ending balance, shares at Jun. 30, 2020 | 282,735,072 | |||||
Beginning balance, value at Dec. 31, 2019 | $ 13,391 | 12,301,739 | (24,530,841) | (12,215,711) | ||
Beginning Balance, shares at Dec. 31, 2019 | 133,912,520 | |||||
Issuance of common shares for converted promissory notes and accrued interest | $ 32,229 | 813,254 | 845,483 | |||
Issuance of common shares for converted promissory notes and accrued interest (in Shares) | 322,286,009 | |||||
Net Income | (140,544,660) | (140,544,660) | ||||
Ending balance, value at Dec. 31, 2020 | $ 45,620 | 13,114,993 | (165,075,501) | (151,914,888) | ||
Ending balance, shares at Dec. 31, 2020 | 456,198,529 | |||||
Issuance of common shares for cash | $ 17,833 | 8,763,868 | 8,781,701 | |||
Issuance of common shares for cash, shares | 178,333,334 | |||||
Issuance of common shares for converted promissory notes and accrued interest | $ 2,196 | 203,779 | 205,975 | |||
Issuance of common shares for converted promissory notes and accrued interest, shares | 21,964,188 | |||||
Issuance of preferred shares for services | $ 100 | 149,700 | 149,800 | |||
Issuance of preferred shares for services (in Shares) | 1,000,000 | |||||
Issuance of preferred shares in exchange for fair value of convertible notes | $ 3 | 85,555,201 | 85,555,204 | |||
Issuance of preferred shares in exchange for fair value of convertible notes, shares | 34,853 | |||||
Issuance of common shares for conversion of preferred stock | $ 2,800 | (2,800) | ||||
Issuance of common shares for conversion of preferred stock, shares | (392) | 28,000,000 | ||||
Stock compensation cost | 17,813,834 | 17,813,834 | ||||
Issuance of common stock warrants deemed dividends | 5,983,504 | (5,983,504) | ||||
Net Income | 47,114,733 | 47,114,733 | ||||
Ending balance, value at Jun. 30, 2021 | $ 3 | $ 68,549 | $ 131,582,079 | $ (123,944,272) | $ 7,706,359 | |
Ending balance, shares at Jun. 30, 2021 | 34,461 | 685,496,051 |
Condensed Statements of Cash Fl
Condensed Statements of Cash Flows - USD ($) | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | Dec. 31, 2019 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||
Net Income (Loss) | $ 47,114,733 | $ (931,259) | $ (140,544,660) | $ 4,122,365 |
Adjustment to reconcile net income(loss) to net cash (used in) provided by operating activities | ||||
Depreciation and amortization expense | 2,182 | 2,182 | 4,365 | 6,890 |
Common stock issued for services | 149,800 | |||
Stock compensation expense | 17,813,834 | 0 | 0 | 0 |
(Gain) Loss on net change in derivative liability | 30,039,479 | 169,011 | 139,038,754 | (5,777,348) |
Amortization of debt discount recognized as interest expense | 449,100 | 320,742 | 611,856 | 673,812 |
Gain on settlement of debt and derivative | (96,666,293) | |||
(Increase) Decrease in Changes in Assets | ||||
Prepaid expenses | (230,772) | 11,854 | (25,479) | (6,849) |
Increase (Decrease) in Changes in Liabilities | ||||
Accounts payable | 530 | 109 | (58) | (838) |
Accrued expenses | 63,033 | 162,843 | 267,924 | 263,565 |
NET CASH USED IN OPERATING ACTIVITIES | (1,264,374) | (264,518) | (647,298) | (718,403) |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
Procceds for the sale of common stock for cash | 8,781,700 | |||
Principal payments on convertible debt | (203,000) | |||
Proceeds from convertible promissory notes | 192,000 | 265,500 | 649,000 | 697,500 |
NET CASH PROVIDED BY FINANCING ACTIVITIES | 8,770,700 | 265,500 | 649,000 | 697,500 |
NET INCREASE (DECREASE) IN CASH | 7,506,326 | 982 | 1,702 | (20,903) |
CASH, BEGINNING OF PERIOD | 63,496 | 61,794 | 61,794 | 82,697 |
CASH, END OF PERIOD | 7,569,822 | 62,776 | 63,496 | 61,794 |
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION | ||||
Interest paid | 439 | 925 | 979 | |
Taxes paid | ||||
SUPPLEMENTAL SCHEDULE OF NON-CASH TRANSACTIONS | ||||
Common stock issued for convertible notes and accrued interest | 205,975 | 413,734 | 845,483 | 662,134 |
Fair value of initial derivative | 180,004 | 265,500 | ||
Fair value of convertible notes exchanged for preferred stock | $ 85,555,204 | |||
Initial debt discount due to derivative | $ 632,144 | $ 663,608 |
Basis of Presentation
Basis of Presentation | 6 Months Ended |
Jun. 30, 2021 | |
Accounting Policies [Abstract] | |
Basis of Presentation | 1. Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. For further information refer to the financial statements and footnotes thereto included in the Company’s Form 10-K for the December 31, 2020. Going Concern The accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The financial statements do not include any adjustment that might result from the outcome of this uncertainty. The ability of the Company to continue as a going concern and appropriateness of using the going concern basis is dependent upon, among other things, achieving a level of profitable operations and receiving additional cash infusions. During the six months ended June 30, 2021, the Company obtained funds from the sale of shares of common stock, and from the issuance of a convertible note agreement. Management believes this funding will continue from its’ current investors and from new investors. Management believes the existing shareholders, and the prospective new investors will provide the additional cash needed to meet the Company’s obligations as they become due and will allow the development of its core business operations. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in case of equity financing. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
Accounting Policies [Abstract] | ||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements. Revenue Recognition The Company will recognize revenue when services are performed, and at the time of shipment of products, provided that evidence of an arrangement exists, title and risk of loss have passed to the customer, fees are fixed or determinable, and collection of the related receivable is reasonably assured. The Company adopted Accounting Standards Codification (“ASC”) 606, whereby revenue will be recognized as performance obligations are satisfied and customers obtain control of goods or services. However, in the event of a loss on a sale is foreseen, the Company will recognize the loss as it is determined. To date, the Company has not had significant revenues and is in the development stage. Cash and Cash Equivalent The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements, include the estimate of useful lives of property and equipment, the deferred tax valuation allowance, derivative liabilities and the fair value of stock options. Actual results could differ from those estimates. Property and Equipment Property and equipment are stated at cost, and are depreciated using straight line over its estimated useful lives: SCHEDULE OF PROPERTY AND EQUIPMENT Computer equipment 5 Years Machinery and equipment 10 Years Depreciation expense for the six months ended June 30, 2021 and 2020 was $ 1,343 1,343 Intangible Assets The Company has patent applications to protect the inventions and processes behind its proprietary bio-based back-sheet, a protective covering for the back of photovoltaic solar modules traditionally made from petroleum-based film. Intangible assets that have finite useful lives continue to be amortized over their useful lives. SCHEDULE OF INTANGIBLE ASSETS AMORTIZED OVER THEIR USEFUL LIVES Useful Lives 2021 2020 Patents $ 45,336 $ 45,336 Less accumulated amortization 15 years (16,623 ) (15,112 ) Intangible assets $ 28,713 $ 30,224 Amortization expense for the six months ended June 30, 2021 and the year ended December 31, 2020 was $ 1,511 3,022 Stock-Based Compensation The Company measures the cost of employee services received in exchange for an equity award based on the grant-date fair value of the award. All grants under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee, consultant, or director are required to provide service in exchange for the award (the vesting period). Compensation expense for options granted to employees and non-employees is determined in accordance with the standard as the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Compensation expense for awards granted is re-measured each period. On March 24, 2015 and September 2, 2015, the Company granted 12,000,000 3,950,000 On February 18, 2021, the Company granted 450,000,000 0.091 The options expire, and all rights to purchase the shares shall terminate seven (7) years from the date of grant or termination of employment. 400,000,000 200,000,000 24 8,333,333 50,000,000 36 1,388,889 NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Stock-Based Compensation Determining the appropriate fair value of the stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based payment and stock price volatility. The Company used Black Scholes to value its stock option awards which incorporated the Company’s stock price, volatility, U.S. risk-free rate, dividend rate, and estimated life. The stock options terminate seven (7) years from the date of grant or upon termination of employment. As of June 30, 2021, 465,950,000 As of June 30, 2021, the Company granted no no Research and Development Research and development costs are expensed as incurred. Total research and development costs were $ 508,440 83,832 Net Earnings (Loss) per Share Calculations Net earnings (Loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the year. Diluted net earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock options and stock-based awards (Note 4), plus the assumed conversion of convertible debt (Note 5). The Company has included shares issuable from convertible debt of $ 107,000 For the six months ended June 30, 2020, the Company’s diluted loss per share is the same as the basic loss per share, and the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. The Company has excluded 15,950,000 2,739,790 SCHEDULE OF NET EARNINGS PER SHARE 2021 2020 For the Six Months Ended June 30, 2021 2020 Income (Loss) to common shareholders (Numerator) $ 46,279,525 $ (931,259 ) Basic weighted average number of common shares outstanding (Denominator) 267,786,651 184,830,379 Diluted weighted average number of common shares outstanding (Denominator) 740,069,136 184,830,379 Fair Value of Financial Instruments Fair Value of Financial Instruments requires disclosure of the fair value information, whether recognized in the balance sheet, where it is practicable to estimate that value. As of June 30, 2021, the amounts reported for cash, inventory, prepaid expenses, accounts payable, and accrued expenses, approximate the fair value because of their short maturities. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include: NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Fair Value of Financial Instruments ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows at June 30, 2021: SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS Total (Level 1) (Level 2) (Level 3) Assets: $ - $ - $ - $ - Liabilities: Derivative Liability at fair value as of June 30, 2021 $ 73,395 $ - $ - $ 73,395 The following is a reconciliation of the derivative liability for which Level 3 inputs were used in determining the approximate fair value: SCHEDULE OF RECONCILIATION OF DERIVATIVE LIABILITY FOR LEVEL 3 INPUTS Balance as of January 31, 2021 $ 148,590,100 Fair value of derivative liabilities issued 180,004 Derecognition of derivative liability (178,736,187 ) Loss on change in derivative liability 30,039,478 Balance as of June 30, 2021 $ 73,395 Accounting for Derivatives The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average series Binomial lattice formula pricing models to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Recently Issued Accounting Pronouncements In May 2021, the FASB issued an amendment to accounting standards ASU 2021-04, (Subtopic 470-50) – Debt Modifications and Extinguishments”, which requires that an entity apply the new guidance to a modification or an exchange of a freestanding equity-classified written call option that is a part of or directly related to a modification or an exchange of an existing debt. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted for all entities. The Company has evaluated the impact of the adoption of ASU 2021-04, which has no effect on the Company’s financial statements. Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements. | 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements. Revenue Recognition The Company will recognize revenue when services are performed, and at the time of shipment of products, provided that evidence of an arrangement exists, title and risk of loss have passed to the customer, fees are fixed or determinable, and collection of the related receivable is reasonably assured. The Company adopted Accounting Standards Codification (“ASC”) 606, whereby revenue will be recognized as performance obligations are satisfied and customers obtain control of goods or services. However, in the event of a loss on a sale is foreseen, the Company will recognize the loss as it is determined. To date, the Company has not had significant revenues and is in the development stage. Cash and Cash Equivalent The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements, include the estimate of useful lives of property and equipment, the deferred tax valuation allowance, derivative liabilities and the fair value of stock options. Actual results could differ from those estimates. BIOSOLAR, INC. NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Property and Equipment Property and equipment are stated at cost, and are depreciated using straight line over its estimated useful lives: SCHEDULE OF PROPERTY AND EQUIPMENT Computer equipment 5 Machinery and equipment 10 Depreciation expense for the years ended December 31, 2020 and 2019 was $ 2,854 4,623 Intangible Assets The Company has patent applications to protect the inventions and processes behind its proprietary bio-based back-sheet, a protective covering for the back of photovoltaic solar modules traditionally made from petroleum-based film. Intangible assets that have finite useful lives continue to be amortized over their useful lives. SCHEDULE OF INTANGIBLE ASSETS AMORTIZED OVER THEIR USEFUL LIVES Useful Lives 2020 2019 Patents $ 45,336 $ 45,336 Less accumulated amortization 15 (15,112 ) (12,090 ) Intangible assets $ 30,224 $ 33,246 Amortization expense for the years ended December 31, 2020 and 2019 was $ 1,511 2,267 Stock-Based Compensation The Company measures the cost of employee services received in exchange for an equity award based on the grant-date fair value of the award. All grants under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee, consultant, or director are required to provide service in exchange for the award (the vesting period). Compensation expense for options granted to employees and non-employees is determined in accordance with the standard as the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Compensation expense for awards granted is re-measured each period. The Company granted 12,000,000 3,950,000 15,950,000 As of December 31, 2020, the Company did not issue any warrants and had no warrants outstanding. Determining the appropriate fair value of the stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based payment and stock price volatility. The Company used Black Scholes to value its stock option awards which incorporated the Company’s stock price, volatility, U.S. risk-free rate, dividend rate, and estimated life. The stock options terminate seven (7) years from the date of grant or upon termination of employment. As of December 31, 2020, 15,950,000 Income Taxes Deferred income taxes are provided using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. On December 22, 2017, the Tax Cut and Jobs Act (the “Tax Act”) was signed into law by the President of the United States. The TCJA is a tax reform act that among other things, reduced corporate income tax rate to 21 21 Research and Development Research and development costs are expensed as incurred. Total research and development costs were $ 177,722 264,687 BIOSOLAR, INC. NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Net Earnings (Loss) per Share Calculations Net earnings (Loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the year. Diluted net earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock options and stock-based awards (Note 4), plus the assumed conversion of convertible debt (Note 5). The Company has excluded shares issuable from convertible debt of $ 2,764,184 15,950,000 The Company has included shares issuable from convertible debt of $ 2,854,033 15,950,000 SCHEDULE OF NET EARNINGS PER SHARE For the Years Ended December 31, 2020 2019 Income (Loss) to common shareholders (Numerator) $ (140,544,660 ) $ (4,122,365 ) Basic weighted average number of common shares outstanding (Denominator) 280,952,034 92,022,751 Diluted weighted average number of common shares outstanding (Denominator) 280,952,034 679,815,020 Fair Value of Financial Instruments Fair Value of Financial Instruments requires disclosure of the fair value information, whether recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2020, the amounts reported for cash, inventory, prepaid expenses, accounts payable, and accrued expenses, approximate the fair value because of their short maturities. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows on December 31, 2020 and 2019: SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS Total (Level 1) (Level 2) (Level 3) Assets: $ - $ - $ - $ - Liabilities: Derivative Liability at fair value as of December 31, 2020 $ 148,590,100 $ - $ - $ 148,590,100 Derivative Liability at fair value as of December 31, 2019 $ 8,919,202 $ - $ - $ 8,919,202 Fair Value of Financial Instruments The following is a reconciliation of the derivative liability for which Level 3 inputs were used in determining the approximate fair value: SCHEDULE OF RECONCILIATION OF DERIVATIVE LIABILITY Balance as of December 31, 2018 $ 14,032,942 Fair value of derivative liabilities issued 663,608 Loss on change in derivative liability (5,777,348 ) Balance as of December 31, 2019 $ 8,919,202 Fair value of derivative liabilities issued 632,144 Loss on change in derivative liability 139,038,754 Balance as of December 31, 2020 $ 148,590,100 BIOSOLAR, INC. NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Accounting for Derivatives The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average series Binomial lattice formula pricing models to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-2, which creates ASC Topic 842, “Leases.” This update increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This guidance is effective for interim and annual reporting periods beginning after December 15, 2018. The Company has evaluated the impact of the adoption of ASC 2016-2, which had no effect on the Company’s financial statements. In June 2018, FASB issued accounting standards update ASU 2018-07, (Topic 505) – “Shared-Based Payment Arrangements with Nonemployees”, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such payments to nonemployees will be aligned with the requirements for share-based payments granted to employees. Under the ASU 2018-07, the measurement of equity-classified nonemployee share-based payments will be fixed on the grant date, as defined in ASC 718, and will use the term nonemployee vesting period, rather than requisite service period. The amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted if financial statements have not yet been issued. The Company has evaluated the impact of the adoption of ASU 2018-07, which has no effect on the Company’s financial statements. In August 2018, the FASB issued to accounting standards update ASU 2018-13, (Topic 820) - “Fair Value Measurement”, which changes the unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted upon issuance. The Company has evaluated the impact of the adoption of ASU 2018-13, which has no effect on the Company’s financial statements. Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements. |
CAPITAL STOCK
CAPITAL STOCK | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
Equity [Abstract] | ||
CAPITAL STOCK | 3. CAPITAL STOCK Preferred Stock On January 14, 2021, the Board of Directors adopted a certificate of designation establishing the rights, preferences, privileges and other terms of 1,000 Series B Preferred Stock, par value $0.0001 per share, providing for supermajority voting rights to holders of the Series B Preferred Stock. 0.10 1,000 On March 26, 2021, the Company entered into an agreement with an investor for an exchange of convertible debt to equity. The investor exchanged convertible notes in the amount of $ 2,462,060 1,023,253 3,485,313 34,853 0.075 206.03 5 SCHEDULE OF EXTINGUISHMENT OF DEBT Per Valuation Preferred shares issued 34,853 Stated value of debt and interest $ 3,485,313 Calculated fair value of preferred shares $ 85,555,204 Fair value of derivative liability removed $ 178,464,388 Gain $ 96,394,494 The Company recognized a gain on settlement of $ 96,394,494 On April 14, 2021, the Board of Directors of the Company authorized the issuance of 1,000 0.0001 no NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 3. CAPITAL STOCK (Continued) Common Stock On June 10, 2021, the Company filed an amendment to its Articles of Incorporation to effect an increase in the authorized number of shares of common stock of the Corporation from 3,000,000,000 0.0001 6,000,000,000 0.0001 During the six months ended June 30, 2021, the Company issued an aggregate of 52,000,000 31,333,334 83,333,334 0.06 During the six months ended June 30, 2021, the Company issued 65,000,000 60,000,000 125,000,000 0.04 During the six months ended June 30, 2021, the Company issued 21,964,188 184,124 20,851 1,000 0.0014 0.0641 During the six months ended June 30, 2021, the Company issued 73,273,212 587,628 74,006 500 0.00495 0.0172 During the six months ended June 30, 2021, the Company issued 1,000,000 During the six months ended June 30, 2021, the Company issued 28,000,000 392 | 3. CAPITAL STOCK Preferred Stock On October 28, 2019, the Board of Directors granted 10,000,000 shares of preferred stock, par value $0.0001 per share, and authorized Series A Preferred stock consisting of one thousand (1,000) shares, which shall not be entitled to receive dividends paid on common stock, no liquidation preference, and no conversion rights. The Series A Preferred Stock will have voting rights for as long as the Series A Preferred Stock remains issued and outstanding, shall have the fifty-one percent (51%) majority voting power of the Company’s shareholders. The Series A Preferred Stock shall be automatically redeemed at par value without any required action by the Company or the holder, and shall be triggered by the following events: (i) A date forty-five (45) days after the effective date of the certificate of designation. (ii) On the date that Mr. Lee ceases for any reason, to serve as officer, director or consultant of the Company. (iii) On the date that the Company’s shares of common stock first trade on any national securities exchange. The Series A Preferred Stock automatically reverted back to the Company at par value on December 12, 2019. As of December 31, 2019, there were no Series A Preferred Stock outstanding. Common Stock On October 28, 2019, the Board of Directors deem it advisable and in the best interest of the Corporation to increase the authorized number of shares of common stock of the Corporation from 500,000,000 0.0001 3,000,000,000 0.0001 During the year ended December 31, 2020, the Company issued 322,286,009 738,850 101,884 4,750 0.0014 0.0074 During the year ended December 31, 2019, the Company issued 73,273,212 587,628 74,006 500 0.00495 0.0172 BIOSOLAR, INC. NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019 |
STOCK OPTIONS
STOCK OPTIONS | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
Share-based Payment Arrangement [Abstract] | ||
STOCK OPTIONS | 4. STOCK OPTIONS Stock Options During the six months ended June 30, 2021, the Company granted 400,000,000 50,000,000 SCHEDULE OF STOCK OPTIONS 6/30/2021 6/30/2020 Number of Options Weighted average exercise price Number of Options Weighted average exercise price Outstanding as of the beginning of the periods 15,950,000 $ 0.23 15,950,000 $ 0.23 Granted 450,000,000 $ 0.028 - - Exercised - - - - Expired - - Outstanding as of the end of the periods 465,950,000 $ 0.035 15,950,000 $ 0.23 Exercisable as of the end of the periods 254,838,889 $ 0.041 15,950,000 $ 0.23 The weighted average remaining contractual life of options outstanding as of June 30, 2021 and 2020 was as follows: SCHEDULE OF WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE OF OPTIONS OUTSTANDING 6/30/2021 6/30/2020 Exercisable Price Stock Options Outstanding Stock Options Exercisable Weighted Average Remaining Contractual Life (years) Exercisable Price Stock Options Outstanding Stock Options Exercisable Weighted Average Remaining Contractual Life (years) $ 0.09 2,450,000 2,450,000 0.73 $ 0.09 2,450,000 2,450,000 1.73 $ 0.26 13,500,000 13,500,000 1.18 $ 0.26 13,500,000 13,500,000 2.18 $ 0.028 450,000,000 238,888,888 6.64 7.64 - - - - 465,950,000 254,838,888 15,950,000 15,950,000 The stock-based compensation expense recognized in the statement of operations during the six months ended June 30, 2021 and 2020, related to the granting of these options was $ 17,813,834 0 As of June 30, 2021 and 2020, respectively, there was no NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 | 4. STOCK OPTIONS Stock Options The Company did not grant any stock options during the years ended December 31, 2020 and 2019, respectively. SCHEDULE OF STOCK OPTIONS 12/31/2020 12/31/2019 Number of Options Weighted average exercise price Number of Options Weighted average exercise price Outstanding as of the beginning of the periods 15,950,000 $ 0.23 15,950,000 $ 0.23 Granted - - - - Exercised - - - - Expired - - - - Outstanding as of the end of the periods 15,950,000 $ 0.23 15,950,000 $ 0.23 Exercisable as of the end of the periods 15,950,000 $ 0.23 15,950,000 $ 0.23 The weighted average remaining contractual life of options outstanding as of December 31, 2020 and 2019 was as follows: SCHEDULE OF WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE OF OPTIONS OUTSTANDING 12/31/2020 12/31/2019 Exercisable Price Stock Options Outstanding Stock Options Exercisable Weighted Average Remaining Contractual Life (years) Exercisable Price Stock Options Outstanding Stock Options Exercisable Weighted Average Remaining Contractual Life (years) $ 0.09 2,450,000 2,450,000 1.23 $ 0.09 2,450,000 2,450,000 2.23 $ 0.26 13,500,000 13,500,000 1.37 $ 0.26 13,500,000 13,500,000 2.37 15,950,000 15,950,000 15,950,000 15,950,000 The stock-based compensation expense recognized in the statement of operations during the years ended December 31, 2020 and 2019, related to the granting of these options was $ 0 0 As of December 31, 2020 and 2019, respectively, there was no intrinsic value with regards to the outstanding options. |
CONVERTIBLE PROMISSORY NOTES
CONVERTIBLE PROMISSORY NOTES | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
Debt Disclosure [Abstract] | ||
CONVERTIBLE PROMISSORY NOTES | 5. CONVERTIBLE PROMISSORY NOTES As of June 30, 2021, the Company’s outstanding convertible promissory notes net of debt discount are summarized as follows: SCHEDULE OF OUTSTANDING CONVERTIBLE PROMISSORY NOTES Convertible Promissory Notes, net of debt discount $ 100,111 Less current portion 100,111 Total long-term liabilities $ - At June 30, 2021, the Company had $ 107,000 6,889 100,111 The Company issued an unsecured convertible promissory note (the May 2014 Note”), in the amount of $ 500,000 September 18, 2019 May 2, 2022 10 The May 2014 Note is convertible into shares of the Company’s common stock at a conversion price of a) the lesser of $0.25 per share of common stock (subject to adjustment for stock splits, dividends, combinations and other similar transactions) or b) fifty percent (50%) of the average three (3) lowest trading prices of three (3) separate trading days recorded after the effective date, or c) the lowest effective price granted to any person or entity after the effective date to acquire common stock. If the Borrower fails to deliver shares in accordance with the time frame of three (3) business days, the Lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to the Borrower. In addition, for each conversion, in the event shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. 1,560 970 0 The Company issued various unsecured convertible promissory notes (the 2015-2018 Notes”) in the aggregate amount of $ 2,145,000 January 30, 2023 10 The 2015-2018 Notes are convertible into shares of the Company’s common stock at conversion prices ranging from the a) the lesser of $0.03 to $0.25 per share of common stock (subject to adjustment for stock splits, dividends, combinations and other similar transactions) or b) fifty percent (50%) of the lowest trade price recorded since the original effective date, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. If the Borrower fails to deliver shares in accordance within the time frame of three (3) business days, the Lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to the Borrower. In addition, for each conversion, in the event shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. 1,960,500 923,717 0 NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 5. CONVERTIBLE PROMISSORY NOTES (Continued) The Company issued various unsecured convertible promissory notes (the Feb 18 Note”) in the aggregate amount of $ 430,000 70,000 500,000 February 18, 2023 10 The Feb 18 Note is convertible into shares of the Company’s common stock at conversion prices ranging from the a) the lesser of $0.03 per share of common stock (subject to adjustment for stock splits, dividends, combinations and other similar transactions) or b) fifty percent (50%) of the lowest trade price recorded since the original effective date, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. If the Borrower fails to deliver shares in accordance with-in the time frame of three (3) business days, the Lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to the Borrower. In addition, for each conversion, in the event shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. 126,134 500,000 98,566 0 The Company issued an unsecured convertible promissory note on August 8, 2019 (the “August 2019 Note”), in the aggregate principal amount of $ 53,500 2,000 51,500 February 14, 2021 10 The August 2019 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest one (1) day trading price or lowest bid price during the fifteen (15) trading days prior to the conversion date. The parties agree that if shares of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the August 2019 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the August 2019 Note. The fair value of the August 2019 Notes has been determined by using the Binomial lattice formula from the effective date of the notes. 21,000,000 40,676 3,000 908,119 12,824 5,564 1,000 0 NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 5. CONVERTIBLE PROMISSORY NOTES (Continued) The Company issued an unsecured convertible promissory note on February 13, 2020 (the “Feb 2020 Note”), in the aggregate principal amount of $ 53,500 2,000 51,500 February 13, 2021 10 The Feb 2020 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest one (1) day trading price or lowest bid price during the fifteen (15) trading days prior to the conversion date. The parties agree that if the shares of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Feb 2020 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Feb 2020 Note. The fair value of the Feb 2020 Note has been determined by using the Binomial lattice formula from the effective date of the notes. 6,578 53,500 The Company issued an unsecured convertible promissory note on July 6, 2020 (the Jul 2020 Note), in the aggregate principal amount of $ 53,000 3,000 50,000 July 6, 2021 10 The Jul 2020 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest average two (2) day closing bid prices during the fifteen (15) trading days prior to the conversion date. The parties agree that if delivery of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Jul 2020 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Jul 2020 Note. The fair value of the Jul 2020 Note has been determined by using the Binomial lattice formula from the effective date of the notes. 27,153 4,062,044 53,000 2,650 0 The Company issued an unsecured convertible promissory note on August 4, 2020 (the Aug 2020 Note), in the aggregate principal amount of $ 53,000 3,000 50,000 August 4, 2021 10 The Aug 2020 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest average two (2) day closing bid prices during the fifteen (15) trading days prior to the conversion date. The parties agree that if delivery of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Aug 2020 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Aug 2020 Note. The fair value of the Aug 2020 Note has been determined by using the Binomial lattice formula from the effective date of the notes. 31,219 868,175 53,000 2,650 0 The Company issued an unsecured convertible promissory note on August 17, 2020 (the “Aug 2020 Note”), in the aggregate principal amount of $ 53,500 2,000 51,500 August 17, 2021 10 The Aug 2020 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest one (1) day trading price or lowest bid price during the fifteen (15) trading days prior to the conversion date. The parties agree that if the shares of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Aug 2020 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Aug 2020 Note. The fair value of the Aug 2020 Note has been determined by using the Binomial lattice formula from the effective date of the notes. 13,338 53,500 NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 5. CONVERTIBLE PROMISSORY NOTES (Continued) The Company issued an unsecured convertible promissory note on September 14, 2020 (the Sep 2020 Note), in the aggregate principal amount of $ 53,000 3,000 50,000 September 14, 2021 10 The Sep 2020 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest average two (2) day closing bid prices during the fifteen (15) trading days prior to the conversion date. The parties agree that if delivery of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Sep 2020 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Sep 2020 Note. The fair value of the Sep 2020 Note has been determined by using the Binomial lattice formula from the effective date of the notes. 37,318 2,100,000 53,000 2,650 0 The Company issued an unsecured convertible promissory note on November 2, 2020 (the Nov 2020 Note), in the aggregate principal amount of $ 53,000 3,000 50,000 November 2, 2021 10 The Nov 2020 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest average two (2) day closing bid prices during the fifteen (15) trading days prior to the conversion date. The parties agree that if delivery of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Nov 2020 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Nov 2020 Note. The fair value of the Nov 2020 Note has been determined by using the Binomial lattice formula from the effective date of the notes. 44,433 0 The Company issued an unsecured convertible promissory note on December 2, 2020 (the Dec 2020 Note), in the aggregate principal amount of $ 53,000 3,000 50,000 December 2, 2021 10 The Dec 2020 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest average two (2) day closing bid prices during the fifteen (15) trading days prior to the conversion date. The parties agree that if delivery of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 5. CONVERTIBLE PROMISSORY NOTES (Continued) The conversion feature of the Dec 2020 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Dec 2020 Note. The fair value of the Dec 2020 Note has been determined by using the Binomial lattice formula from the effective date of the notes. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $ 3,416 0 The Company issued an unsecured convertible promissory note on January 4, 2021 (the Jan 4, 2021 Note), in the aggregate principal amount of $ 53,500 3,000 50,000 January 4, 2021 10 The Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest average two (2) day closing bid prices during the fifteen (15) trading days prior to the conversion date. The parties agree that if delivery of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Jan 4 2021 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Jan 4 2021 Note. The fair value of the Jan 4 2021 Note has been determined by using the Binomial lattice formula from the effective date of the notes. 53,500 0 The Company issued an unsecured convertible promissory note on January 14, 2021 (the Jan 14 2021 Note), in the aggregate principal amount of $ 53,500 3,000 50,000 January 14, 2021 10 The Jan 14 2021 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest average two (2) day closing bid prices during the fifteen (15) trading days prior to the conversion date. The parties agree that if delivery of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Jan 14 2021 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Jan 14 2021 Note. The fair value of the Jan 14 2021 Note has been determined by using the Binomial lattice formula from the effective date of the notes. 53,500 0 During the period ended June 30, 2021, the Company exchanged convertible notes in the amount of $ 2,462,060 in principal, plus accrued interest of $ 1,023,253 for 34,853 shares of Series C Preferred Shares. In addition, the Company repaid convertible notes in the amount of $ 203,000 52,780 We evaluated the financing transactions in accordance with ASC Topic 815, Derivatives and Hedging, and determined that the conversion feature of the convertible promissory note was not afforded the exemption for conventional convertible instruments due to its variable conversion rate. The note has no explicit limit on the number of shares issuable, so they did not meet the conditions set forth in current accounting standards for equity classification. The Company elected to recognize the note under paragraph 815-15-25-4, whereby, there would be a separation into a host contract and derivative instrument. The Company elected to initially and subsequently measure the note in its entirety at fair value, with changes in fair value recognized in earnings. The Company recorded a derivative liability representing the imputed interest associated with the embedded derivative. The derivative liability is adjusted periodically per the stock price fluctuations. NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 | 5. CONVERTIBLE PROMISSORY NOTES As of December 31, 2020 and 2019, the outstanding convertible promissory notes net of debt discount are summarized as follows: SCHEDULE OF OUTSTANDING CONVERTIBLE PROMISSORY NOTES 2020 2019 Convertible Promissory Notes, net of debt discount $ 2,764,184 $ 2,598,336 Less current portion 275,985 390,987 Total long-term liabilities $ 2,488,199 $ 2,207,349 Maturities of long-term debt, net of debt discount for the next five years are as follows: SCHEDULE OF MATURITIES OF LONG-TERM DEBT, NET OF DEBT DISCOUNT December 31, Amount 2021 $ 1,289,824 2022 473,560 2023 900,800 2024 25,000 2025 75,000 Total long-term debt $ 2,764,184 On December 31, 2020, the Company had $ 2,764,184 275,985 2,488,199 BIOSOLAR, INC. NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019 5. CONVERTIBLE PROMISSORY NOTES (Continued) The Company issued an unsecured convertible promissory note (the May 2014 Note”), in the amount of $ 500,000 September 18, 2019 The May 2014 Note bears interest at 10 100,105,926 96,590 54,460 1,560 The Company issued various unsecured convertible promissory notes (the 2015-2018 Notes”) in the aggregate amount of $ 2,145,000 January 30, 2023 10 The 2015-2018 Notes are convertible into shares of the Company’s common stock at conversion prices ranging from the a) the lesser of $0.03 to $0.25 per share of common stock (subject to adjustment for stock splits, dividends, combinations and other similar transactions) or b) fifty percent (50%) of the lowest trade price recorded since the original effective date, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. If the Borrower fails to deliver shares in accordance with the time frame of three (3) business days, the Lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to the Borrower. In addition, for each conversion, in the event shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. 801 30,836,986 27,200 15,972 1,957,800 The Company issued various unsecured convertible promissory notes (the Feb 18 Note”) in the aggregate amount of $ 355,000 75,000 430,000 10 The Feb 18 Note is convertible into shares of the Company’s common stock at conversion prices ranging from the a) the lesser of $0.03 per share of common stock (subject to adjustment for stock splits, dividends, combinations and other similar transactions) or b) fifty percent (50%) of the lowest trade price recorded since the original effective date, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. If the Borrower fails to deliver shares in accordance with-in the time frame of three (3) business days, the Lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to the Borrower. In addition, for each conversion, in the event shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. 2,810 430,000 The Company issued various unsecured convertible promissory notes (the “Feb-Apr 2019 Notes”) in the aggregate principal amount of $ 107,000 4,000 103,000 10 34,267,881 72,384 6,351 1,750 The Feb-Apr 2019 Note was converted based on the terms of the agreement, and the Company did not recognize a gain or loss on conversion in the financials. 21,801 BIOSOLAR, INC. NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019 5. CONVERTIBLE PROMISSORY NOTES (Continued) The Company issued an unsecured convertible promissory note on July 16, 2019 (the “July 2019 Note”), in the aggregate principal amount of $ 53,000 3,000 50,000 10 8,248,918 53,000 2,650 28,672 The Company issued an unsecured convertible promissory note on August 8, 2019 (the “August 2019 Note”), in the aggregate principal amount of $ 53,500 2,000 51,500 10 21,000,000 40,676 3,000 32,305 12,824 The Company issued an unsecured convertible promissory note on August 29, 2019 (the “August 29, 2019 Note”), in the aggregate principal amount of $ 63,000 3,000 60,000 10 13,624,762 63,000 3,150 24,408 The Company issued an unsecured convertible promissory note on October 1, 2019 (the “Oct 2019 Note”), in the aggregate principal amount of $ 63,000 3,000 60,000 10 28,413,462 63,000 3,150 47,336 BIOSOLAR, INC. NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018 5. CONVERTIBLE PROMISSORY NOTES (Continued) The Company issued an unsecured convertible promissory note on November 4, 2019 (the “Nov 2019 Note”), in the aggregate principal amount of $ 58,000 3,000 55,000 10 24,588,385 58,000 2,900 48,967 The Company issued an unsecured convertible promissory note on December 20, 2019 (the “Dec 2019 Note”), in the aggregate principal amount of $ 53,000 3,000 50,000 10 21,118,946 53,000 2,650 51,407 The Company issued an unsecured convertible promissory note on January 23, 2020 (the “Jan 2020 Note”), in the aggregate principal amount of $ 53,000 3,000 50,000 10 12,320,494 53,000 2,650 The Jan 2020 Note was converted based on the terms of the agreement and the Company did not recognize a gain or loss on the conversion in the financials. 53,000 The Company issued an unsecured convertible promissory note on February 13, 2020 (the “Feb 2020 Note”), in the aggregate principal amount of $ 53,500 2,000 51,500 10 33,474 53,500 BIOSOLAR, INC. NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018 5. CONVERTIBLE PROMISSORY NOTES (Continued) The Company issued an unsecured convertible promissory note on March 2, 2020 (the “Mar 2020 Note”), in the aggregate principal amount of $ 53,000 3,000 50,000 10 7,520,270 53,000 2,650 The Mar 2020 Note was converted based on the terms of the agreement and the Company did not recognize a gain or loss on the conversion in the financials. 53,000 The Company issued an unsecured convertible promissory note on April 28, 2020 (the “Apr 2020 Note”), in the aggregate principal amount of $ 53,000 3,000 50,000 10 12,616,691 53,000 2,650 The Apr 2020 Note was converted based on the terms of the agreement and the Company did not recognize a gain or loss on the conversion in the financials. 53,000 The Company issued an unsecured convertible promissory note on June 22, 2020 (the Jun 2020 Note), in the aggregate principal amount of $ 53,000 3,000 10 7,623,288 53,000 2,650 The Jun 2020 Note was converted based on the terms of the agreement and the Company did not recognize a gain or loss on the conversion in the financials. 53,000 The Company issued an unsecured convertible promissory note on July 6, 2020 (the Jul 2020 Note), in the aggregate principal amount of $ 53,000 3,000 50,000 10 25,847 53,000 BIOSOLAR, INC. NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018 5. CONVERTIBLE PROMISSORY NOTES (Continued) The Company issued an unsecured convertible promissory note on August 4, 2020 (the Aug 2020 Note), in the aggregate principal amount of $ 53,000 3,000 50,000 10 21,781 53,000 The Company issued an unsecured convertible promissory note on September 14, 2020 (the Sep 2020 Note), in the aggregate principal amount of $ 53,000 3,000 50,000 10 15,682 53,000 The Company issued an unsecured convertible promissory note on November 2, 2020 (the Nov 2020 Note), in the aggregate principal amount of $ 53,000 3,000 50,000 10 8,567 53,000 The Company issued an unsecured convertible promissory note on December 2, 2020 (the Dec 2020 Note), in the aggregate principal amount of $ 53,000 3,000 50,000 10 43,000 BIOSOLAR, INC. NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018 5. CONVERTIBLE PROMISSORY NOTES (Continued) We evaluated the financing transactions in accordance with ASC Topic 815, Derivatives and Hedging, and determined that the conversion feature of the convertible promissory note was not afforded the exemption for conventional convertible instruments due to its variable conversion rate. The note has no explicit limit on the number of shares issuable, so they did not meet the conditions set forth in current accounting standards for equity classification. The Company elected to recognize the note under paragraph 815-15-25-4, whereby, there would be a separation into a host contract and derivative instrument. The Company elected to initially and subsequently measure the note in its entirety at fair value, with changes in fair value recognized in earnings. The Company recorded a derivative liability representing the imputed interest associated with the embedded derivative. The derivative liability is adjusted periodically per the stock price fluctuations. |
DERIVATIVE LIABILITIES
DERIVATIVE LIABILITIES | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ||
DERIVATIVE LIABILITIES | 6. DERIVATIVE LIABILITIES We evaluated the financing transactions in accordance with ASC Topic 815, Derivatives and Hedging, and determined that the conversion feature of the convertible promissory note was not afforded the exemption for conventional convertible instruments due to its variable conversion rate. The note has no explicit limit on the number of shares issuable, so they did not meet the conditions set forth in current accounting standards for equity classification. The Company elected to recognize the note under paragraph 815-15-25-4, whereby, there would be a separation into a host contract and derivative instrument. The Company elected to initially and subsequently measure the note in its entirety at fair value, with changes in fair value recognized in earnings. The Company recorded a derivative liability representing the imputed interest associated with the embedded derivative. The derivative liability is adjusted periodically per the stock price fluctuations. The convertible notes issued and described in Note 5 do not have fixed settlement provisions because their conversion prices are not fixed. The conversion feature has been characterized as derivative liabilities to be re-measured at the end of every reporting period with the change in value reported in the statement of operations. During the six months ended June 30, 2021, as a result of the convertible notes (“Notes”) issued that were accounted for as derivative liabilities, we determined that the fair value of the conversion feature of the convertible notes at issuance was $ 180,004 During the six months ended June 30, 2021, the Company converted $ 184,124 20,851 1,000 638,936 30,039,479 73,395 For purpose of determining the fair market value of the derivative liability for the embedded conversion, the Company used the Binomial lattice valuation model. The significant assumptions used in the Binomial lattice valuation model for the derivative are as follows: SCHEDULE OF DERIVATIVE LIABILITIES VALUATION ASSUMPTIONS 6/30/2021 Risk free interest rate 0.05 Stock volatility factor 63.0 65.0 Weighted average expected option life 6 1 Expected dividend yield None Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry-forwards for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry-forwards may be limited as to use in future years. | 6. DERIVATIVE LIABILITIES We evaluated the financing transactions in accordance with ASC Topic 815, Derivatives and Hedging, and determined that the conversion feature of the convertible promissory note was not afforded the exemption for conventional convertible instruments due to its variable conversion rate. The note has no explicit limit on the number of shares issuable, so they did not meet the conditions set forth in current accounting standards for equity classification. The Company elected to recognize the note under paragraph 815-15-25-4, whereby, there would be a separation into a host contract and derivative instrument. The Company elected to initially and subsequently measure the note in its entirety at fair value, with changes in fair value recognized in earnings. The Company recorded a derivative liability representing the imputed interest associated with the embedded derivative. The derivative liability is adjusted periodically per the stock price fluctuations. The convertible notes issued and described in Note 5 do not have fixed settlement provisions because their conversion prices are not fixed. The conversion feature has been characterized as derivative liabilities to be re-measured at the end of every reporting period with the change in value reported in the statement of operations. During the year ended December 31, 2020, as a result of the convertible notes (“Notes”) issued that were accounted for as derivative liabilities, we determined that the fair value of the conversion feature of the convertible notes at issuance was $ 632,143 During the year ended December 31, 2020, the Company converted $ 738,850 101,884 4,750 632,144 139,038,754 148,590,100 For purpose of determining the fair market value of the derivative liability for the embedded conversion, the Company used the Binomial lattice valuation model. The significant assumptions used in the Binomial lattice valuation model for the derivative are as follows: SCHEDULE OF DERIVATIVE LIABILITIES VALUATION ASSUMPTIONS 12/31/2020 Risk free interest rate 0.08 0.17 Stock volatility factor 164.0 247.0 Weighted average expected option life 6 5 Expected dividend yield None |
RELATED PARTY TRANSACTION
RELATED PARTY TRANSACTION | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
Related Party Transactions [Abstract] | ||
RELATED PARTY TRANSACTION | 7. RELATED PARTY TRANSACTION On January 14, 2021, the Company issued 1,000 no 0.10 1,000 no NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 On April 14, 2021, the Company issued 1,000 0.10 1,000 no | 8. RELATED PARTY TRANSACTION On October 28, 2019, the Company issued 1,000 20 The Series A Preferred Stock had a fifty-one (51%) voting right only and was redeemed at par value on December 12, 2019 no |
SECURITIES PURCHASE AGREEMENT
SECURITIES PURCHASE AGREEMENT | 6 Months Ended |
Jun. 30, 2021 | |
Securities Purchase Agreement | |
SECURITIES PURCHASE AGREEMENT | 8. SECURITIES PURCHASE AGREEMENT On January 27, 2021, the Company entered into a securities purchase agreement with an investor to sell through a private placement an aggregate of 52,000,000 31,333,334 83,333,334 0.06 In addition, the combined purchase price of $ 0.06 0.0599 4,996,866 5,000,000 5,000,000 4,406,217 3,133 4,409,350 In connection with the closing, the Company issued an additional 6,250,000 0.075 July 27, 2026 On April 4, 2021, the Company entered into a securities purchase agreement with an investor to sell through a direct registered offering an aggregate of 65,000,000 60,000,000 125,000,000 0.04 In addition, the combined purchase price of $ 0.04 0.0399 4,994,000 5,000,000 5,000,000 4,369,350 3,000 4,372,350 30,000,000 In connection with the closing, the Company issued an additional 9,375,000 0.05 April 4, 2026 SCHEDULE OF WARRANTS ACITIVITY 6/30/2021 Number of Warrants Weighted average exercise price Outstanding as of the beginning of the periods - - Issued 315,291,668 $ 0.048 Purchased 61,333,334 - Expired - - Outstanding as of the end of the periods 253,958,334 $ 0.048 Exercisable as of the end of the periods 253,958,334 $ 0.048 NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 The weighted average remaining contractual life of the warrants outstanding as of June 30, 2021 was as follows: SCHEDULE OF WARRANTS OUTSTANDING 6/30/2021 Exercisable Price Stock Warrants Outstanding Stock Warrants Exercisable Weighted Average Remaining Contractual Life (years) $ 0.0001 30,000,000 30,000,000 4.77 $ 0.04 125,000,000 125,000,000 4.77 $ 0.05 9,375,000 9,375,000 4.76 $ 0.06 83,333,334 83,333,334 5.08 $ 0.075 6,250,000 6,250,000 5.08 253,958,334 253,958,334 |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | ||
COMMITMENTS AND CONTINGENCIES | 9. COMMITMENTS AND CONTINGENCIES The Company rents office space on a yearly basis with a monthly rent payment in the amount of $ 550 In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. In the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the Company’s financial position or results of operations. As of June 30, 2021, there were no legal proceedings against the Company. | 9. COMMITMENTS AND CONTINGENCIES The Company rents office space on a yearly basis with a monthly rent payment in the amount of $ 550 In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. In the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the Company’s financial position or results of operations. As of December 31, 2020, there were no legal proceedings against the Company. |
SUBSEQUENT EVENT
SUBSEQUENT EVENT | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
Subsequent Events [Abstract] | ||
SUBSEQUENT EVENT | 10. SUBSEQUENT EVENT Management has evaluated subsequent events according to the requirements of ASC TOPIC 855 and has determined that there are no subsequent events to report. On July 20, 2021, the Company issued 30,000,000 0.0001 | 10. SUBSEQUENT EVENT Management has evaluated subsequent events according to the requirements of ASC TOPIC 855 and has determined that there are the following subsequent events: On January 4, 2021, the Company entered into a convertible promissory note with an investor providing for the sale by the Company of a 10 53,500 The Jan 2021 Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of 61% of the average of the two lowest (2) day trading prices for common stock during the fifteen (15) trading day period prior to the conversion date On January 7, 2021, the Company issued 4,062,044 53,000 2,650 On January 15, 2021, the Company issued 14,025,851 12,300 7,336 On January 13, 2021, the Company received additional consideration on the convertible note dated February 26, 2018 in the amount of $ 50,000 On January 14, 2021, the Company entered into a convertible promissory note with an investor providing for the sale by the Company of a 10 53,500 The Feb 2021 Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of 61% of the average of the two lowest (2) day trading prices for common stock during the fifteen (15) trading day period prior to the conversion date. On January 27, 2021, the Company entered into a securities purchase agreement with an investor to sell through a private placement an aggregate of 52,000,000 31,333,334 83,333,334 5,000,000 0.06 0.0599 On February 4, 2021, the Company issued 868,175 53,000 2,650 On February 5, 2021, the Company issued 908,118 12,824 5,564 1,000 On February 5, 2021, the Company issued 1,000,000 |
ORGANIZATION AND LINE OF BUSINE
ORGANIZATION AND LINE OF BUSINESS | 6 Months Ended |
Jun. 30, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
ORGANIZATION AND LINE OF BUSINESS | 1. ORGANIZATION AND LINE OF BUSINESS Organization BioSolar, Inc. (the “Company”) was incorporated in the state of Nevada on April 24, 2006. The Company, based in Santa Clarita, California, began operations on April 25, 2006 to develop and market Photovoltaic solar technology products. Line of Business We are a developer of clean energy technologies. Our current focus is on developing an electrolyzer technology to lower the cost of Green Hydrogen production. We are developing technologies to significantly reduce or replace rare earth materials with inexpensive earth abundant materials in electrolyzers to help usher in a Green Hydrogen economy. We are also developing innovative technologies to increase the storage capacity, lower the cost and extend the life of lithium-ion batteries for electric vehicles or EV. We previously developed BioBacksheet R Going Concern The accompanying financial statements have been prepared on a going concern basis of accounting, which contemplates continuity of operations, realization of assets and liabilities and commitments in the normal course of business. The accompanying financial statements do not reflect any adjustments that might result if the Company is unable to continue as a going concern. During the year ended December 31, 2020, the Company did not generate any revenue, incurred net loss of $ 140,544,660 139,038,754 647,298 150,532,859 151,914,888 The accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The financial statements do not include any adjustment that might result from the outcome of this uncertainty. The ability of the Company to continue as a going concern and appropriateness of using the going concern basis is dependent upon, among other things, achieving a level of profitable operations and receiving additional cash infusions. During the year ended December 31, 2020, the Company obtained funds from the issuance of convertible note agreements. Management believes this funding will continue from its’ current investors and from new investors. Management believes the existing shareholders, and the prospective new investors will provide the additional cash needed to meet the Company’s obligations as they become due and will allow the development of its core business operations. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in case of equity financing. |
INCOME TAXES
INCOME TAXES | 12 Months Ended |
Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | |
INCOME TAXES | 7. INCOME TAXES On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the “Act”), which significantly changed U.S. tax law. The Act lowered the Company’s U.S. statutory federal income tax rate from 35 21 The Company files income tax returns in the U.S. Federal jurisdiction, and the state of California. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before 2017. Included in the balance on December 31, 2020, are no tax positions for which the ultimate deductibility is highly certain, but for which there is uncertainty about the timing of such deductibility. Because of the impact of deferred tax accounting, other than interest and penalties, the disallowance of the shorter deductibility period would not affect the annual effective tax rate but would accelerate the payment of cash to the taxing authority to an earlier period. BIOSOLAR, INC. NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019 7. INCOME TAXES (Continued) The Company’s policy is to recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. During the year ended December 31, 2020, the Company did not recognize interest and penalties. As of December 31, 2020, the Company had net operating loss carry-forwards of approximately $ 9,890,000 The income tax provision differs from the amount of income tax determined by applying the U.S. federal and state income tax rate of 30 SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE 2020 2019 Book Income (Loss) (29,514,380 ) 1,236,710 Non-deductible expenses 29,381,500 (1,013,080 ) Valuation Allowance 132,880 (223,630 ) Income tax expense $ - $ - Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible differences and operating loss and tax credit carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the difference between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Net deferred tax assets consist of the following components as of December 31, 2020 and 2019: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2020 2019 Deferred tax assets: NOL carryover (2,076,950 ) (1,947,750 ) R & D credit 166,875 142,385 Depreciation 10,735 10,735 Deferred tax liabilities: - Less Valuation Allowance 1,899,340 1794,630 Net deferred tax asset $ - $ - Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry-forwards for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry-forwards may be limited as to use in future years. BIOSOLAR, INC. NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019 |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
Accounting Policies [Abstract] | ||
Revenue Recognition | Revenue Recognition The Company will recognize revenue when services are performed, and at the time of shipment of products, provided that evidence of an arrangement exists, title and risk of loss have passed to the customer, fees are fixed or determinable, and collection of the related receivable is reasonably assured. The Company adopted Accounting Standards Codification (“ASC”) 606, whereby revenue will be recognized as performance obligations are satisfied and customers obtain control of goods or services. However, in the event of a loss on a sale is foreseen, the Company will recognize the loss as it is determined. To date, the Company has not had significant revenues and is in the development stage. | Revenue Recognition The Company will recognize revenue when services are performed, and at the time of shipment of products, provided that evidence of an arrangement exists, title and risk of loss have passed to the customer, fees are fixed or determinable, and collection of the related receivable is reasonably assured. The Company adopted Accounting Standards Codification (“ASC”) 606, whereby revenue will be recognized as performance obligations are satisfied and customers obtain control of goods or services. However, in the event of a loss on a sale is foreseen, the Company will recognize the loss as it is determined. To date, the Company has not had significant revenues and is in the development stage. |
Cash and Cash Equivalent | Cash and Cash Equivalent The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) | Cash and Cash Equivalent The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements, include the estimate of useful lives of property and equipment, the deferred tax valuation allowance, derivative liabilities and the fair value of stock options. Actual results could differ from those estimates. | Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements, include the estimate of useful lives of property and equipment, the deferred tax valuation allowance, derivative liabilities and the fair value of stock options. Actual results could differ from those estimates. BIOSOLAR, INC. NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) |
Property and Equipment | Property and Equipment Property and equipment are stated at cost, and are depreciated using straight line over its estimated useful lives: SCHEDULE OF PROPERTY AND EQUIPMENT Computer equipment 5 Years Machinery and equipment 10 Years Depreciation expense for the six months ended June 30, 2021 and 2020 was $ 1,343 1,343 | Property and Equipment Property and equipment are stated at cost, and are depreciated using straight line over its estimated useful lives: SCHEDULE OF PROPERTY AND EQUIPMENT Computer equipment 5 Machinery and equipment 10 Depreciation expense for the years ended December 31, 2020 and 2019 was $ 2,854 4,623 |
Intangible Assets | Intangible Assets The Company has patent applications to protect the inventions and processes behind its proprietary bio-based back-sheet, a protective covering for the back of photovoltaic solar modules traditionally made from petroleum-based film. Intangible assets that have finite useful lives continue to be amortized over their useful lives. SCHEDULE OF INTANGIBLE ASSETS AMORTIZED OVER THEIR USEFUL LIVES Useful Lives 2021 2020 Patents $ 45,336 $ 45,336 Less accumulated amortization 15 years (16,623 ) (15,112 ) Intangible assets $ 28,713 $ 30,224 Amortization expense for the six months ended June 30, 2021 and the year ended December 31, 2020 was $ 1,511 3,022 | Intangible Assets The Company has patent applications to protect the inventions and processes behind its proprietary bio-based back-sheet, a protective covering for the back of photovoltaic solar modules traditionally made from petroleum-based film. Intangible assets that have finite useful lives continue to be amortized over their useful lives. SCHEDULE OF INTANGIBLE ASSETS AMORTIZED OVER THEIR USEFUL LIVES Useful Lives 2020 2019 Patents $ 45,336 $ 45,336 Less accumulated amortization 15 (15,112 ) (12,090 ) Intangible assets $ 30,224 $ 33,246 Amortization expense for the years ended December 31, 2020 and 2019 was $ 1,511 2,267 |
Stock-Based Compensation | Stock-Based Compensation The Company measures the cost of employee services received in exchange for an equity award based on the grant-date fair value of the award. All grants under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee, consultant, or director are required to provide service in exchange for the award (the vesting period). Compensation expense for options granted to employees and non-employees is determined in accordance with the standard as the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Compensation expense for awards granted is re-measured each period. On March 24, 2015 and September 2, 2015, the Company granted 12,000,000 3,950,000 On February 18, 2021, the Company granted 450,000,000 0.091 The options expire, and all rights to purchase the shares shall terminate seven (7) years from the date of grant or termination of employment. 400,000,000 200,000,000 24 8,333,333 50,000,000 36 1,388,889 NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Stock-Based Compensation Determining the appropriate fair value of the stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based payment and stock price volatility. The Company used Black Scholes to value its stock option awards which incorporated the Company’s stock price, volatility, U.S. risk-free rate, dividend rate, and estimated life. The stock options terminate seven (7) years from the date of grant or upon termination of employment. As of June 30, 2021, 465,950,000 As of June 30, 2021, the Company granted no no | Stock-Based Compensation The Company measures the cost of employee services received in exchange for an equity award based on the grant-date fair value of the award. All grants under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee, consultant, or director are required to provide service in exchange for the award (the vesting period). Compensation expense for options granted to employees and non-employees is determined in accordance with the standard as the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Compensation expense for awards granted is re-measured each period. The Company granted 12,000,000 3,950,000 15,950,000 As of December 31, 2020, the Company did not issue any warrants and had no warrants outstanding. Determining the appropriate fair value of the stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based payment and stock price volatility. The Company used Black Scholes to value its stock option awards which incorporated the Company’s stock price, volatility, U.S. risk-free rate, dividend rate, and estimated life. The stock options terminate seven (7) years from the date of grant or upon termination of employment. As of December 31, 2020, 15,950,000 |
Research and Development | Research and Development Research and development costs are expensed as incurred. Total research and development costs were $ 508,440 83,832 | Research and Development Research and development costs are expensed as incurred. Total research and development costs were $ 177,722 264,687 BIOSOLAR, INC. NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) |
Net Earnings (Loss) per Share Calculations | Net Earnings (Loss) per Share Calculations Net earnings (Loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the year. Diluted net earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock options and stock-based awards (Note 4), plus the assumed conversion of convertible debt (Note 5). The Company has included shares issuable from convertible debt of $ 107,000 For the six months ended June 30, 2020, the Company’s diluted loss per share is the same as the basic loss per share, and the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. The Company has excluded 15,950,000 2,739,790 SCHEDULE OF NET EARNINGS PER SHARE 2021 2020 For the Six Months Ended June 30, 2021 2020 Income (Loss) to common shareholders (Numerator) $ 46,279,525 $ (931,259 ) Basic weighted average number of common shares outstanding (Denominator) 267,786,651 184,830,379 Diluted weighted average number of common shares outstanding (Denominator) 740,069,136 184,830,379 | Net Earnings (Loss) per Share Calculations Net earnings (Loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the year. Diluted net earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock options and stock-based awards (Note 4), plus the assumed conversion of convertible debt (Note 5). The Company has excluded shares issuable from convertible debt of $ 2,764,184 15,950,000 The Company has included shares issuable from convertible debt of $ 2,854,033 15,950,000 SCHEDULE OF NET EARNINGS PER SHARE For the Years Ended December 31, 2020 2019 Income (Loss) to common shareholders (Numerator) $ (140,544,660 ) $ (4,122,365 ) Basic weighted average number of common shares outstanding (Denominator) 280,952,034 92,022,751 Diluted weighted average number of common shares outstanding (Denominator) 280,952,034 679,815,020 |
Fair Value of Financial Instruments | Fair Value of Financial Instruments Fair Value of Financial Instruments requires disclosure of the fair value information, whether recognized in the balance sheet, where it is practicable to estimate that value. As of June 30, 2021, the amounts reported for cash, inventory, prepaid expenses, accounts payable, and accrued expenses, approximate the fair value because of their short maturities. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include: NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Fair Value of Financial Instruments ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows at June 30, 2021: SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS Total (Level 1) (Level 2) (Level 3) Assets: $ - $ - $ - $ - Liabilities: Derivative Liability at fair value as of June 30, 2021 $ 73,395 $ - $ - $ 73,395 The following is a reconciliation of the derivative liability for which Level 3 inputs were used in determining the approximate fair value: SCHEDULE OF RECONCILIATION OF DERIVATIVE LIABILITY FOR LEVEL 3 INPUTS Balance as of January 31, 2021 $ 148,590,100 Fair value of derivative liabilities issued 180,004 Derecognition of derivative liability (178,736,187 ) Loss on change in derivative liability 30,039,478 Balance as of June 30, 2021 $ 73,395 | Fair Value of Financial Instruments Fair Value of Financial Instruments requires disclosure of the fair value information, whether recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2020, the amounts reported for cash, inventory, prepaid expenses, accounts payable, and accrued expenses, approximate the fair value because of their short maturities. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows on December 31, 2020 and 2019: SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS Total (Level 1) (Level 2) (Level 3) Assets: $ - $ - $ - $ - Liabilities: Derivative Liability at fair value as of December 31, 2020 $ 148,590,100 $ - $ - $ 148,590,100 Derivative Liability at fair value as of December 31, 2019 $ 8,919,202 $ - $ - $ 8,919,202 Fair Value of Financial Instruments The following is a reconciliation of the derivative liability for which Level 3 inputs were used in determining the approximate fair value: SCHEDULE OF RECONCILIATION OF DERIVATIVE LIABILITY Balance as of December 31, 2018 $ 14,032,942 Fair value of derivative liabilities issued 663,608 Loss on change in derivative liability (5,777,348 ) Balance as of December 31, 2019 $ 8,919,202 Fair value of derivative liabilities issued 632,144 Loss on change in derivative liability 139,038,754 Balance as of December 31, 2020 $ 148,590,100 BIOSOLAR, INC. NOTES TO FINANCIAL STATEMENTS – AUDITED FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) |
Accounting for Derivatives | Accounting for Derivatives The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average series Binomial lattice formula pricing models to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. NEWHYDROGEN, INC. (FORMERLY BIOSOLAR, INC.) NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) | Accounting for Derivatives The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average series Binomial lattice formula pricing models to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. |
Recently Issued Accounting Pronouncements | Recently Issued Accounting Pronouncements In May 2021, the FASB issued an amendment to accounting standards ASU 2021-04, (Subtopic 470-50) – Debt Modifications and Extinguishments”, which requires that an entity apply the new guidance to a modification or an exchange of a freestanding equity-classified written call option that is a part of or directly related to a modification or an exchange of an existing debt. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted for all entities. The Company has evaluated the impact of the adoption of ASU 2021-04, which has no effect on the Company’s financial statements. Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements. | Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-2, which creates ASC Topic 842, “Leases.” This update increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This guidance is effective for interim and annual reporting periods beginning after December 15, 2018. The Company has evaluated the impact of the adoption of ASC 2016-2, which had no effect on the Company’s financial statements. In June 2018, FASB issued accounting standards update ASU 2018-07, (Topic 505) – “Shared-Based Payment Arrangements with Nonemployees”, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such payments to nonemployees will be aligned with the requirements for share-based payments granted to employees. Under the ASU 2018-07, the measurement of equity-classified nonemployee share-based payments will be fixed on the grant date, as defined in ASC 718, and will use the term nonemployee vesting period, rather than requisite service period. The amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted if financial statements have not yet been issued. The Company has evaluated the impact of the adoption of ASU 2018-07, which has no effect on the Company’s financial statements. In August 2018, the FASB issued to accounting standards update ASU 2018-13, (Topic 820) - “Fair Value Measurement”, which changes the unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted upon issuance. The Company has evaluated the impact of the adoption of ASU 2018-13, which has no effect on the Company’s financial statements. Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements. |
Income Taxes | Income Taxes Deferred income taxes are provided using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. On December 22, 2017, the Tax Cut and Jobs Act (the “Tax Act”) was signed into law by the President of the United States. The TCJA is a tax reform act that among other things, reduced corporate income tax rate to 21 21 |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
Accounting Policies [Abstract] | ||
SCHEDULE OF PROPERTY AND EQUIPMENT | Property and equipment are stated at cost, and are depreciated using straight line over its estimated useful lives: SCHEDULE OF PROPERTY AND EQUIPMENT Computer equipment 5 Years Machinery and equipment 10 Years | Property and equipment are stated at cost, and are depreciated using straight line over its estimated useful lives: SCHEDULE OF PROPERTY AND EQUIPMENT Computer equipment 5 Machinery and equipment 10 |
SCHEDULE OF INTANGIBLE ASSETS AMORTIZED OVER THEIR USEFUL LIVES | SCHEDULE OF INTANGIBLE ASSETS AMORTIZED OVER THEIR USEFUL LIVES Useful Lives 2021 2020 Patents $ 45,336 $ 45,336 Less accumulated amortization 15 years (16,623 ) (15,112 ) Intangible assets $ 28,713 $ 30,224 | SCHEDULE OF INTANGIBLE ASSETS AMORTIZED OVER THEIR USEFUL LIVES Useful Lives 2020 2019 Patents $ 45,336 $ 45,336 Less accumulated amortization 15 (15,112 ) (12,090 ) Intangible assets $ 30,224 $ 33,246 |
SCHEDULE OF NET EARNINGS PER SHARE | SCHEDULE OF NET EARNINGS PER SHARE 2021 2020 For the Six Months Ended June 30, 2021 2020 Income (Loss) to common shareholders (Numerator) $ 46,279,525 $ (931,259 ) Basic weighted average number of common shares outstanding (Denominator) 267,786,651 184,830,379 Diluted weighted average number of common shares outstanding (Denominator) 740,069,136 184,830,379 | SCHEDULE OF NET EARNINGS PER SHARE For the Years Ended December 31, 2020 2019 Income (Loss) to common shareholders (Numerator) $ (140,544,660 ) $ (4,122,365 ) Basic weighted average number of common shares outstanding (Denominator) 280,952,034 92,022,751 Diluted weighted average number of common shares outstanding (Denominator) 280,952,034 679,815,020 |
SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS | We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows at June 30, 2021: SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS Total (Level 1) (Level 2) (Level 3) Assets: $ - $ - $ - $ - Liabilities: Derivative Liability at fair value as of June 30, 2021 $ 73,395 $ - $ - $ 73,395 | SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS Total (Level 1) (Level 2) (Level 3) Assets: $ - $ - $ - $ - Liabilities: Derivative Liability at fair value as of December 31, 2020 $ 148,590,100 $ - $ - $ 148,590,100 Derivative Liability at fair value as of December 31, 2019 $ 8,919,202 $ - $ - $ 8,919,202 |
SCHEDULE OF RECONCILIATION OF DERIVATIVE LIABILITY | The following is a reconciliation of the derivative liability for which Level 3 inputs were used in determining the approximate fair value: SCHEDULE OF RECONCILIATION OF DERIVATIVE LIABILITY FOR LEVEL 3 INPUTS Balance as of January 31, 2021 $ 148,590,100 Fair value of derivative liabilities issued 180,004 Derecognition of derivative liability (178,736,187 ) Loss on change in derivative liability 30,039,478 Balance as of June 30, 2021 $ 73,395 | SCHEDULE OF RECONCILIATION OF DERIVATIVE LIABILITY Balance as of December 31, 2018 $ 14,032,942 Fair value of derivative liabilities issued 663,608 Loss on change in derivative liability (5,777,348 ) Balance as of December 31, 2019 $ 8,919,202 Fair value of derivative liabilities issued 632,144 Loss on change in derivative liability 139,038,754 Balance as of December 31, 2020 $ 148,590,100 |
CAPITAL STOCK (Tables)
CAPITAL STOCK (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Equity [Abstract] | |
SCHEDULE OF EXTINGUISHMENT OF DEBT | SCHEDULE OF EXTINGUISHMENT OF DEBT Per Valuation Preferred shares issued 34,853 Stated value of debt and interest $ 3,485,313 Calculated fair value of preferred shares $ 85,555,204 Fair value of derivative liability removed $ 178,464,388 Gain $ 96,394,494 |
STOCK OPTIONS (Tables)
STOCK OPTIONS (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
Share-based Payment Arrangement [Abstract] | ||
SCHEDULE OF STOCK OPTIONS | SCHEDULE OF STOCK OPTIONS 6/30/2021 6/30/2020 Number of Options Weighted average exercise price Number of Options Weighted average exercise price Outstanding as of the beginning of the periods 15,950,000 $ 0.23 15,950,000 $ 0.23 Granted 450,000,000 $ 0.028 - - Exercised - - - - Expired - - Outstanding as of the end of the periods 465,950,000 $ 0.035 15,950,000 $ 0.23 Exercisable as of the end of the periods 254,838,889 $ 0.041 15,950,000 $ 0.23 | SCHEDULE OF STOCK OPTIONS 12/31/2020 12/31/2019 Number of Options Weighted average exercise price Number of Options Weighted average exercise price Outstanding as of the beginning of the periods 15,950,000 $ 0.23 15,950,000 $ 0.23 Granted - - - - Exercised - - - - Expired - - - - Outstanding as of the end of the periods 15,950,000 $ 0.23 15,950,000 $ 0.23 Exercisable as of the end of the periods 15,950,000 $ 0.23 15,950,000 $ 0.23 |
SCHEDULE OF WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE OF OPTIONS OUTSTANDING | The weighted average remaining contractual life of options outstanding as of June 30, 2021 and 2020 was as follows: SCHEDULE OF WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE OF OPTIONS OUTSTANDING 6/30/2021 6/30/2020 Exercisable Price Stock Options Outstanding Stock Options Exercisable Weighted Average Remaining Contractual Life (years) Exercisable Price Stock Options Outstanding Stock Options Exercisable Weighted Average Remaining Contractual Life (years) $ 0.09 2,450,000 2,450,000 0.73 $ 0.09 2,450,000 2,450,000 1.73 $ 0.26 13,500,000 13,500,000 1.18 $ 0.26 13,500,000 13,500,000 2.18 $ 0.028 450,000,000 238,888,888 6.64 7.64 - - - - 465,950,000 254,838,888 15,950,000 15,950,000 | SCHEDULE OF WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE OF OPTIONS OUTSTANDING 12/31/2020 12/31/2019 Exercisable Price Stock Options Outstanding Stock Options Exercisable Weighted Average Remaining Contractual Life (years) Exercisable Price Stock Options Outstanding Stock Options Exercisable Weighted Average Remaining Contractual Life (years) $ 0.09 2,450,000 2,450,000 1.23 $ 0.09 2,450,000 2,450,000 2.23 $ 0.26 13,500,000 13,500,000 1.37 $ 0.26 13,500,000 13,500,000 2.37 15,950,000 15,950,000 15,950,000 15,950,000 |
CONVERTIBLE PROMISSORY NOTES (T
CONVERTIBLE PROMISSORY NOTES (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
Debt Disclosure [Abstract] | ||
SCHEDULE OF OUTSTANDING CONVERTIBLE PROMISSORY NOTES | As of June 30, 2021, the Company’s outstanding convertible promissory notes net of debt discount are summarized as follows: SCHEDULE OF OUTSTANDING CONVERTIBLE PROMISSORY NOTES Convertible Promissory Notes, net of debt discount $ 100,111 Less current portion 100,111 Total long-term liabilities $ - | As of December 31, 2020 and 2019, the outstanding convertible promissory notes net of debt discount are summarized as follows: SCHEDULE OF OUTSTANDING CONVERTIBLE PROMISSORY NOTES 2020 2019 Convertible Promissory Notes, net of debt discount $ 2,764,184 $ 2,598,336 Less current portion 275,985 390,987 Total long-term liabilities $ 2,488,199 $ 2,207,349 |
SCHEDULE OF MATURITIES OF LONG-TERM DEBT, NET OF DEBT DISCOUNT | SCHEDULE OF MATURITIES OF LONG-TERM DEBT, NET OF DEBT DISCOUNT December 31, Amount 2021 $ 1,289,824 2022 473,560 2023 900,800 2024 25,000 2025 75,000 Total long-term debt $ 2,764,184 |
DERIVATIVE LIABILITIES (Tables)
DERIVATIVE LIABILITIES (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ||
SCHEDULE OF DERIVATIVE LIABILITIES VALUATION ASSUMPTIONS | For purpose of determining the fair market value of the derivative liability for the embedded conversion, the Company used the Binomial lattice valuation model. The significant assumptions used in the Binomial lattice valuation model for the derivative are as follows: SCHEDULE OF DERIVATIVE LIABILITIES VALUATION ASSUMPTIONS 6/30/2021 Risk free interest rate 0.05 Stock volatility factor 63.0 65.0 Weighted average expected option life 6 1 Expected dividend yield None | For purpose of determining the fair market value of the derivative liability for the embedded conversion, the Company used the Binomial lattice valuation model. The significant assumptions used in the Binomial lattice valuation model for the derivative are as follows: SCHEDULE OF DERIVATIVE LIABILITIES VALUATION ASSUMPTIONS 12/31/2020 Risk free interest rate 0.08 0.17 Stock volatility factor 164.0 247.0 Weighted average expected option life 6 5 Expected dividend yield None |
SECURITIES PURCHASE AGREEMENT (
SECURITIES PURCHASE AGREEMENT (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Securities Purchase Agreement | |
SCHEDULE OF WARRANTS ACITIVITY | SCHEDULE OF WARRANTS ACITIVITY 6/30/2021 Number of Warrants Weighted average exercise price Outstanding as of the beginning of the periods - - Issued 315,291,668 $ 0.048 Purchased 61,333,334 - Expired - - Outstanding as of the end of the periods 253,958,334 $ 0.048 Exercisable as of the end of the periods 253,958,334 $ 0.048 |
SCHEDULE OF WARRANTS OUTSTANDING | The weighted average remaining contractual life of the warrants outstanding as of June 30, 2021 was as follows: SCHEDULE OF WARRANTS OUTSTANDING 6/30/2021 Exercisable Price Stock Warrants Outstanding Stock Warrants Exercisable Weighted Average Remaining Contractual Life (years) $ 0.0001 30,000,000 30,000,000 4.77 $ 0.04 125,000,000 125,000,000 4.77 $ 0.05 9,375,000 9,375,000 4.76 $ 0.06 83,333,334 83,333,334 5.08 $ 0.075 6,250,000 6,250,000 5.08 253,958,334 253,958,334 |
INCOME TAXES (Tables)
INCOME TAXES (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | |
SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE | SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE 2020 2019 Book Income (Loss) (29,514,380 ) 1,236,710 Non-deductible expenses 29,381,500 (1,013,080 ) Valuation Allowance 132,880 (223,630 ) Income tax expense $ - $ - |
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES | Net deferred tax assets consist of the following components as of December 31, 2020 and 2019: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2020 2019 Deferred tax assets: NOL carryover (2,076,950 ) (1,947,750 ) R & D credit 166,875 142,385 Depreciation 10,735 10,735 Deferred tax liabilities: - Less Valuation Allowance 1,899,340 1794,630 Net deferred tax asset $ - $ - |
SCHEDULE OF PROPERTY AND EQUIPM
SCHEDULE OF PROPERTY AND EQUIPMENT (Details) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
Computer Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, Useful lives | 5 years | 5 years |
Machinery and Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, Useful lives | 10 years | 10 years |
SCHEDULE OF INTANGIBLE ASSETS A
SCHEDULE OF INTANGIBLE ASSETS AMORTIZED OVER THEIR USEFUL LIVES (Details) - USD ($) | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Accounting Policies [Abstract] | |||
Patents | $ 45,336 | $ 45,336 | $ 45,336 |
Less accumulated amortization | $ (16,623) | $ (15,112) | (12,090) |
Patents, Useful Lives | 15 years | 15 years | |
Intangible assets | $ 28,713 | $ 30,224 | $ 33,246 |
SCHEDULE OF NET EARNINGS PER SH
SCHEDULE OF NET EARNINGS PER SHARE (Details) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | Dec. 31, 2019 | |
Accounting Policies [Abstract] | ||||||
Income (Loss) to common shareholders (Numerator) | $ 46,279,525 | $ (931,259) | ||||
Basic weighted average number of common shares outstanding (Denominator) | 659,726,820 | 223,425,846 | 267,786,651 | 184,830,379 | 280,952,034 | 92,022,751 |
Diluted weighted average number of common shares outstanding (Denominator) | 659,726,820 | 2,124,796,718 | 740,069,136 | 184,830,379 | 280,952,034 | 679,815,020 |
Income (Loss) to common shareholders (Numerator) (in Dollars) | $ (3,654,944) | $ 6,134,253 | $ 47,114,733 | $ (931,259) | $ (140,544,660) | $ 4,122,365 |
Income (Loss) to common shareholders (Numerator) (in Dollars) | $ 3,654,944 | $ (6,134,253) | $ (47,114,733) | $ 931,259 | $ 140,544,660 | $ (4,122,365) |
SCHEDULE OF ASSETS AND LIABILIT
SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Defined Benefit Plan Disclosure [Line Items] | |||
Assets | |||
Derivative Liability at fair value | 73,395 | 148,590,100 | $ 8,919,202 |
Fair Value, Inputs, Level 1 [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Assets | |||
Derivative Liability at fair value | |||
Fair Value, Inputs, Level 2 [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Assets | |||
Derivative Liability at fair value | |||
Fair Value, Inputs, Level 3 [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Assets | |||
Derivative Liability at fair value | $ 73,395 | $ 148,590,100 | $ 8,919,202 |
SCHEDULE OF RECONCILIATION OF D
SCHEDULE OF RECONCILIATION OF DERIVATIVE LIABILITY FOR LEVEL 3 INPUTS (Details) - USD ($) | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Accounting Policies [Abstract] | |||
Beginning Balance | $ 148,590,100 | $ 8,919,202 | $ 14,032,942 |
Fair value of derivative liabilities issued | 180,004 | 632,144 | 663,608 |
Derecognition Of Derivative Liability | (178,736,187) | ||
Loss on change in derivative liability | 30,039,478 | (139,038,754) | 5,777,348 |
Ending Balance | $ 73,395 | $ 148,590,100 | $ 8,919,202 |
SUMMARY OF SIGNIFICANT ACCOUN_4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) | Mar. 18, 2021 | Feb. 18, 2021 | Sep. 02, 2015 | Mar. 24, 2015 | Dec. 22, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] | ||||||||||||
Depreciation expense | $ 1,343 | $ 1,343 | $ 2,854 | $ 4,623 | ||||||||
Amortization expense | $ 1,511 | $ 3,022 | ||||||||||
Stock options, exercise price | $ 0.041 | $ 0.23 | $ 0.041 | $ 0.23 | $ 0.23 | $ 0.23 | ||||||
Stock options exercisable, shares | 254,838,889 | 15,950,000 | 254,838,889 | 15,950,000 | 15,950,000 | 15,950,000 | ||||||
Stock options, outstanding | 465,950,000 | 15,950,000 | 465,950,000 | 15,950,000 | 15,950,000 | 15,950,000 | 15,950,000 | |||||
Warrants Granted | $ 0 | |||||||||||
Warrants Outstanding | $ 0 | 0 | ||||||||||
Research and development costs | 251,776 | $ 40,212 | 508,440 | $ 83,832 | $ 177,722 | $ 264,687 | ||||||
Share issuable from convertible debt | $ 107,000 | |||||||||||
Antidilutive securities excluded from computation of earnings per share, amount (in Shares) | 15,950,000 | |||||||||||
Convertible debt | $ 2,739,790 | $ 2,739,790 | ||||||||||
Amortization expense | $ 1,511 | 2,267 | ||||||||||
Corporate income tax rate | 21.00% | |||||||||||
Convertible Debt Securities [Member] | ||||||||||||
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] | ||||||||||||
Issuable from convertible debt | $ 2,764,184 | $ 2,854,033 | ||||||||||
Share-based Payment Arrangement, Option [Member] | ||||||||||||
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] | ||||||||||||
Stock options granted (in Shares) | 12,000,000 | |||||||||||
Stock options board of directors for services | $ 3,950,000 | |||||||||||
Outstanding stock options (in Shares) | 15,950,000 | |||||||||||
Employee Stock [Member] | ||||||||||||
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] | ||||||||||||
Antidilutive securities excluded from computation of earnings per share, amount (in Shares) | 15,950,000 | 15,950,000 | ||||||||||
Outstanding stock options (in Shares) | 15,950,000 | |||||||||||
Corporate income tax rate | 21.00% | |||||||||||
Employee [Member] | ||||||||||||
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] | ||||||||||||
Stock options granted (in Shares) | 450,000,000 | 12,000,000 | ||||||||||
Stock options, exercise price | $ 0.091 | |||||||||||
Stock options, expiration or termination description | The options expire, and all rights to purchase the shares shall terminate seven (7) years from the date of grant or termination of employment. | |||||||||||
Vesting stock options | 400,000,000 | |||||||||||
Employee [Member] | First Installment Twenty Four Months [Member] | ||||||||||||
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] | ||||||||||||
Vesting stock options | 8,333,333 | |||||||||||
Stock options exercisable, shares | 200,000,000 | |||||||||||
Stock options exercisable period | 24 months | |||||||||||
Employee [Member] | First Installment Thirty Six Months [Member] | ||||||||||||
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] | ||||||||||||
Vesting stock options | 1,388,889 | |||||||||||
Stock options exercisable, shares | 50,000,000 | |||||||||||
Stock options exercisable period | 36 months | |||||||||||
Board of Directors Chairman [Member] | ||||||||||||
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] | ||||||||||||
Stock options granted (in Shares) | 3,950,000 |
SCHEDULE OF EXTINGUISHMENT OF D
SCHEDULE OF EXTINGUISHMENT OF DEBT (Details) - USD ($) | Mar. 26, 2021 | Jun. 30, 2021 | Dec. 31, 2020 |
Equity [Abstract] | |||
Debt conversion, shares | 34,853 | ||
Stated value of debt and interest | $ 3,485,313 | ||
Calculated fair value of preferred shares | 85,555,204 | ||
Fair value of derivative liability removed | 178,464,388 | $ 638,936 | $ 632,144 |
Gain on settlement | $ 96,394,494 |
CAPITAL STOCK (Details Narrativ
CAPITAL STOCK (Details Narrative) | Jun. 30, 2021USD ($)$ / sharesshares | Apr. 04, 2021$ / sharesshares | Mar. 26, 2021USD ($)$ / sharesshares | Jan. 27, 2021$ / sharesshares | Jan. 14, 2021$ / sharesshares | Jun. 30, 2021USD ($)$ / sharesshares | Jun. 30, 2020USD ($)shares | Dec. 31, 2020USD ($)$ / sharesshares | Dec. 31, 2019USD ($)$ / sharesshares | Jun. 10, 2021$ / sharesshares | Jun. 09, 2021$ / sharesshares | Apr. 14, 2021$ / sharesshares | Oct. 28, 2019$ / sharesshares | Oct. 27, 2019shares |
Class of Stock [Line Items] | ||||||||||||||
Preferred stock, shares authorized | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 | ||||||||||
Debt conversion, principal amount | $ | $ 107,000 | |||||||||||||
Debt conversion, principal and interest amount | $ | $ 3,485,313 | |||||||||||||
Common stock issued | 34,853 | |||||||||||||
Gain on settlement | $ | $ 96,394,494 | |||||||||||||
Preferred stock, shares outstanding | 0 | 0 | ||||||||||||
Common stock, shares authorized | 3,000,000,000 | 3,000,000,000 | 3,000,000,000 | 3,000,000,000 | 6,000,000,000 | 3,000,000,000 | ||||||||
Common stock, par value | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||
Warrants to purchase common stock | 30,000,000 | 30,000,000 | ||||||||||||
Amount of debt conversion | $ | $ 205,975 | $ 413,734 | ||||||||||||
Increase authorized number of shares of common stock | 3,000,000,000 | 500,000,000 | ||||||||||||
Convertible Promissory Notes [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Common stock issued | 21,964,188 | |||||||||||||
Amount of debt conversion | $ | $ 184,124 | |||||||||||||
Accrued interest | $ | 20,851 | |||||||||||||
Other fees | $ | $ 1,000 | $ 1,000 | ||||||||||||
Convertible Promissory Notes Two [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Common stock issued | 73,273,212 | |||||||||||||
Amount of debt conversion | $ | $ 587,628 | |||||||||||||
Accrued interest | $ | 74,006 | |||||||||||||
Other fees | $ | $ 500 | $ 500 | ||||||||||||
Convertible Debt [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Common stock issued | 322,286,009 | 73,273,212 | ||||||||||||
Amount of debt conversion | $ | $ 7,388,500,000 | $ 5,876,280,000 | ||||||||||||
Accrued interest | $ | 1,018,840,000 | 740,060,000 | ||||||||||||
Other fees | $ | $ 47,500,000 | $ 5,000,000 | ||||||||||||
Maximum [Member] | Convertible Promissory Notes [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Common stock conversion price per share | $ / shares | $ 0.0641 | $ 0.0641 | ||||||||||||
Maximum [Member] | Convertible Promissory Notes Two [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Common stock conversion price per share | $ / shares | 0.0172 | 0.0172 | ||||||||||||
Maximum [Member] | Convertible Debt [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Common stock conversion price per share | $ / shares | $ 0.0074 | $ 0.00495 | ||||||||||||
Minimum [Member] | Convertible Promissory Notes [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Common stock conversion price per share | $ / shares | 0.0014 | 0.0014 | ||||||||||||
Minimum [Member] | Convertible Promissory Notes Two [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Common stock conversion price per share | $ / shares | 0.00495 | $ 0.00495 | ||||||||||||
Minimum [Member] | Convertible Debt [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Common stock conversion price per share | $ / shares | $ 0.0014 | $ 0.0172 | ||||||||||||
Common Stock [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Common stock issued | 21,964,188 | 148,822,552 | ||||||||||||
Shares issued during the period private placement | 178,333,334 | |||||||||||||
Amount of debt conversion | $ | $ 2,196 | $ 14,882 | ||||||||||||
Share issued for services | 1,000,000 | |||||||||||||
Shares issued for conversion of preferred stock | 28,000,000 | |||||||||||||
Preferred Stock [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Common stock issued | ||||||||||||||
Amount of debt conversion | $ | ||||||||||||||
Share issued for services | 1,000 | |||||||||||||
Shares issued for conversion of preferred stock | 392 | |||||||||||||
Securities Purchase Agreement [Member] | Warrant [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Exercise price | $ / shares | $ 0.05 | $ 0.075 | ||||||||||||
Warrants to purchase common stock | 9,375,000 | 6,250,000 | ||||||||||||
Investor [Member] | Securities Purchase Agreement [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Exercise price | $ / shares | $ 0.06 | $ 0.04 | $ 0.06 | $ 0.06 | ||||||||||
Shares issued during the period private placement | 65,000,000 | 52,000,000 | 52,000,000 | |||||||||||
Investor [Member] | Securities Purchase Agreement [Member] | Common Stock [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Exercise price | $ / shares | $ 0.04 | $ 0.06 | ||||||||||||
Investor [Member] | Securities Purchase Agreement [Member] | Common Stock [Member] | Maximum [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Shares issued during the period private placement | 60,000,000 | 31,333,334 | 31,333,334 | |||||||||||
Investor [Member] | Securities Purchase Agreement [Member] | Warrant [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Exercise price | $ / shares | $ 0.0399 | $ 0.0599 | ||||||||||||
Warrants to purchase common stock | 5,000,000 | 5,000,000 | ||||||||||||
Investor [Member] | Securities Purchase Agreement [Member] | Warrant [Member] | Maximum [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Warrants to purchase common stock | 83,333,334 | 125,000,000 | 83,333,334 | 83,333,334 | ||||||||||
Investor [Member] | Securities Purchase Agreement One [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Exercise price | $ / shares | $ 0.04 | $ 0.04 | ||||||||||||
Shares issued during the period private placement | 65,000,000 | |||||||||||||
Investor [Member] | Securities Purchase Agreement One [Member] | Common Stock [Member] | Maximum [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Shares issued during the period private placement | 60,000,000 | |||||||||||||
Investor [Member] | Securities Purchase Agreement One [Member] | Warrant [Member] | Maximum [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Shares issued during the period private placement | 125,000,000 | |||||||||||||
Series B Preferred Stock [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Preferred stock, rights description | the Board of Directors adopted a certificate of designation establishing the rights, preferences, privileges and other terms of 1,000 Series B Preferred Stock, par value $0.0001 per share, providing for supermajority voting rights to holders of the Series B Preferred Stock. | |||||||||||||
Exercise price | $ / shares | $ 0.10 | |||||||||||||
Preferred stock, shares authorized | 1,000 | |||||||||||||
Preferred stock, shares outstanding | 0 | 0 | ||||||||||||
Series C Preferred Stock [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Debt conversion, principal amount | $ | 2,462,060 | |||||||||||||
Debt conversion, interest amount | $ | 1,023,253 | |||||||||||||
Debt conversion, principal and interest amount | $ | $ 3,485,313 | |||||||||||||
Stock price | $ / shares | $ 0.075 | |||||||||||||
Gain on settlement | $ | $ 96,394,494 | |||||||||||||
Preferred stock, shares outstanding | 34,461 | 34,461 | 34,461 | |||||||||||
Series C Preferred Stock [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Equity security measurement input | 2.0603 | |||||||||||||
Series D Preferred Stock [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Preferred stock, shares outstanding | 0 | 0 | ||||||||||||
Series D Preferred Stock [Member] | David Lee [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Exercise price | $ / shares | $ 0.0001 | |||||||||||||
Preferred stock, shares authorized | 1,000 |
SCHEDULE OF STOCK OPTIONS (Deta
SCHEDULE OF STOCK OPTIONS (Details) - $ / shares | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | Dec. 31, 2019 | |
Share-based Payment Arrangement [Abstract] | ||||
Number of Options, Outstanding as of the beginning of the periods | 15,950,000 | 15,950,000 | 15,950,000 | 15,950,000 |
Weighted average exercise price, Outstanding as of the beginning of the periods | $ 0.23 | $ 0.23 | $ 0.23 | $ 0.23 |
Number of Options, Granted | 450,000,000 | |||
Weighted average exercise price, Granted | $ 0.028 | |||
Number of Options, Exercised | ||||
Weighted average exercise price, Exercised | ||||
Number of Options, Expired | ||||
Weighted average exercise price, Expired | ||||
Number of Options, Outstanding as of the end of the periods | 465,950,000 | 15,950,000 | 15,950,000 | 15,950,000 |
Weighted average exercise price, Outstanding as of the end of the periods | $ 0.035 | $ 0.23 | $ 0.23 | $ 0.23 |
Number of Options, Exercisable, End Balance | 254,838,889 | 15,950,000 | 15,950,000 | 15,950,000 |
Weighted average exercise price, Exercisable, End Balance | $ 0.041 | $ 0.23 | $ 0.23 | $ 0.23 |
Number of Options, Exercisable as of the end of the periods | 254,838,889 | 15,950,000 | 15,950,000 | 15,950,000 |
Weighted average exercise price, Exercisable as of the end of the periods | $ 0.041 | $ 0.23 | $ 0.23 | $ 0.23 |
SCHEDULE OF WEIGHTED AVERAGE RE
SCHEDULE OF WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE OF OPTIONS OUTSTANDING (Details) - $ / shares | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | Dec. 31, 2019 | |
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||||
Stock Options Outstanding | 465,950,000 | 15,950,000 | 15,950,000 | 15,950,000 |
Stock Options Exercisable | 254,838,888 | 15,950,000 | 15,950,000 | 15,950,000 |
Exercisable Prices One [Member]. | ||||
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||||
Exercisable Price (in Dollars per share) | $ 0.09 | $ 0.09 | $ 0.09 | $ 0.09 |
Stock Options Outstanding | 2,450,000 | 2,450,000 | 2,450,000 | 2,450,000 |
Stock Options Exercisable | 2,450,000 | 2,450,000 | 2,450,000 | 2,450,000 |
Weighted Average Remaining Contractual Life (years) | 8 months 23 days | 1 year 8 months 23 days | 1 year 4 months 13 days | 2 years 2 months 23 days |
ExercisablePricesTwoMember | ||||
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||||
Exercisable Price (in Dollars per share) | $ 0.26 | $ 0.26 | $ 0.26 | $ 0.26 |
Stock Options Outstanding | 13,500,000 | 13,500,000 | 13,500,000 | 13,500,000 |
Stock Options Exercisable | 13,500,000 | 13,500,000 | 13,500,000 | 13,500,000 |
Weighted Average Remaining Contractual Life (years) | 1 year 2 months 4 days | 2 years 2 months 4 days | 1 year 2 months 23 days | 2 years 4 months 13 days |
Exercisable Prices Three [Member] | ||||
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||||
Exercisable Price (in Dollars per share) | $ 0.028 | |||
Stock Options Outstanding | 450,000,000 | |||
Stock Options Exercisable | 238,888,888 | |||
Weighted Average Remaining Contractual Life (years) | 0 years | |||
Exercisable Prices Three [Member] | Minimum [Member] | ||||
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||||
Weighted Average Remaining Contractual Life (years) | 6 years 7 months 20 days | |||
Exercisable Prices Three [Member] | Maximum [Member] | ||||
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] | ||||
Weighted Average Remaining Contractual Life (years) | 7 years 7 months 20 days |
STOCK OPTIONS (Details Narrativ
STOCK OPTIONS (Details Narrative) - USD ($) | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | Dec. 31, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock options, granted | 450,000,000 | |||
Stock-based compensation expense | $ 17,813,834 | $ 0 | $ 0 | $ 0 |
Outstanding options, intrinsic value | $ 0 | $ 0 | ||
Share-based Payment Arrangement, Employee [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock options, granted | 50,000,000 | |||
Chief Executive Officer [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock options, granted | 400,000,000 |
SCHEDULE OF OUTSTANDING CONVERT
SCHEDULE OF OUTSTANDING CONVERTIBLE PROMISSORY NOTES (Details) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Debt Disclosure [Abstract] | |||
Convertible Promissory Notes, net of debt discount | $ 100,111 | $ 2,764,184 | $ 2,598,336 |
Less current portion | 100,111 | 275,985 | 390,987 |
Total long-term liabilities | $ 2,488,199 | $ 2,207,349 |
CONVERTIBLE PROMISSORY NOTES (D
CONVERTIBLE PROMISSORY NOTES (Details Narrative) - USD ($) | Mar. 26, 2021 | Jan. 14, 2021 | Jan. 04, 2021 | Dec. 02, 2020 | Nov. 02, 2020 | Sep. 14, 2020 | Sep. 14, 2020 | Aug. 17, 2020 | Aug. 04, 2020 | Aug. 04, 2020 | Jul. 06, 2020 | Jul. 06, 2020 | Mar. 02, 2020 | Feb. 13, 2020 | Feb. 13, 2020 | Dec. 26, 2019 | Nov. 04, 2019 | Oct. 01, 2019 | Aug. 08, 2019 | Aug. 08, 2019 | May 02, 2014 | Apr. 28, 2020 | Jan. 23, 2020 | Dec. 20, 2019 | Aug. 29, 2019 | Jul. 16, 2019 | Feb. 28, 2018 | Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | Dec. 31, 2019 | Feb. 09, 2018 | Feb. 23, 2021 | Jun. 22, 2020 | Mar. 31, 2020 | Dec. 22, 2018 |
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible promissory notes | $ 107,000 | $ 107,000 | $ 2,764,184 | |||||||||||||||||||||||||||||||||||
Convertible promissory notes debt discount | 6,889 | 6,889 | 219,850 | $ 254,896 | ||||||||||||||||||||||||||||||||||
Convertible promissory notes net | 100,111 | 100,111 | 1,069,974 | 390,987 | ||||||||||||||||||||||||||||||||||
Debt instrument face amount | 184,124 | 184,124 | 738,850 | |||||||||||||||||||||||||||||||||||
Shares of common stock upon conversion of principal amount | 205,975 | $ 413,734 | ||||||||||||||||||||||||||||||||||||
Accrued interest | 20,851 | 101,884 | ||||||||||||||||||||||||||||||||||||
Issuance of common shares for converted promissory notes and accrued interest, shares | 34,853 | |||||||||||||||||||||||||||||||||||||
Other fees | 1,000 | 4,750 | ||||||||||||||||||||||||||||||||||||
Interest expense | 15,977 | $ 231,874 | $ 563,914 | $ 457,187 | 876,229 | $ 954,774 | ||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible promissory notes debt discount | 275,985 | |||||||||||||||||||||||||||||||||||||
Convertible promissory notes net | 2,488,199 | |||||||||||||||||||||||||||||||||||||
Series C Preferred Stock [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Debt Conversion Shares Amount | 34,853 | |||||||||||||||||||||||||||||||||||||
May 2014 Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible promissory notes net | 0 | $ 0 | 1,560 | |||||||||||||||||||||||||||||||||||
Debt instrument face amount | $ 500,000 | |||||||||||||||||||||||||||||||||||||
Debt instrument maturity date | May 2, 2022 | Sep. 18, 2019 | ||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||
Debt instrument conversion price description | The May 2014 Note is convertible into shares of the Company’s common stock at a conversion price of a) the lesser of $0.25 per share of common stock (subject to adjustment for stock splits, dividends, combinations and other similar transactions) or b) fifty percent (50%) of the average three (3) lowest trading prices of three (3) separate trading days recorded after the effective date, or c) the lowest effective price granted to any person or entity after the effective date to acquire common stock. If the Borrower fails to deliver shares in accordance with the time frame of three (3) business days, the Lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to the Borrower. In addition, for each conversion, in the event shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. | |||||||||||||||||||||||||||||||||||||
Shares of common stock upon conversion of principal amount | 1,560 | 96,590 | ||||||||||||||||||||||||||||||||||||
Accrued interest | 970 | $ 54,460 | ||||||||||||||||||||||||||||||||||||
Issuance of common shares for converted promissory notes and accrued interest, shares | 100,105,926 | |||||||||||||||||||||||||||||||||||||
May 2014 Note [Member] | Convertible Notes Payable [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Debt instrument conversion price description | The May 2014 Note bears interest at 10% per annum. The May 2014 Note is convertible into shares of the Company’s common stock at a conversion price of a) the lesser of $0.25 per share of common stock (subject to adjustment for stock splits, dividends, combinations and other similar transactions) or b) fifty percent (50%) of the average three (3) lowest trading prices of three (3) separate trading days recorded after the effective date, or c) the lowest effective price granted to any person or entity after the effective date to acquire common stock. If the Borrower fails to deliver shares in accordance with the time frame of three (3) business days, the Lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to the Borrower. In addition, for each conversion, in the event shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. | |||||||||||||||||||||||||||||||||||||
2015-2018 Notes [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible promissory notes debt discount | $ 801 | |||||||||||||||||||||||||||||||||||||
Convertible promissory notes net | 0 | 0 | ||||||||||||||||||||||||||||||||||||
Debt instrument face amount | $ 2,145,000 | |||||||||||||||||||||||||||||||||||||
Debt instrument maturity date | Jan. 30, 2023 | |||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||
Debt instrument conversion price description | The 2015-2018 Notes are convertible into shares of the Company’s common stock at conversion prices ranging from the a) the lesser of $0.03 to $0.25 per share of common stock (subject to adjustment for stock splits, dividends, combinations and other similar transactions) or b) fifty percent (50%) of the lowest trade price recorded since the original effective date, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. If the Borrower fails to deliver shares in accordance within the time frame of three (3) business days, the Lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to the Borrower. In addition, for each conversion, in the event shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. | |||||||||||||||||||||||||||||||||||||
Shares of common stock upon conversion of principal amount | 1,960,500 | 27,200 | ||||||||||||||||||||||||||||||||||||
Accrued interest | 923,717 | $ 15,972 | ||||||||||||||||||||||||||||||||||||
Issuance of common shares for converted promissory notes and accrued interest, shares | 30,836,986 | |||||||||||||||||||||||||||||||||||||
2015-2018 Notes [Member] | Convertible Notes Payable [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Debt instrument conversion price description | The 2015-2018 Notes are convertible into shares of the Company’s common stock at conversion prices ranging from the a) the lesser of $0.03 to $0.25 per share of common stock (subject to adjustment for stock splits, dividends, combinations and other similar transactions) or b) fifty percent (50%) of the lowest trade price recorded since the original effective date, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. If the Borrower fails to deliver shares in accordance with the time frame of three (3) business days, the Lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to the Borrower. In addition, for each conversion, in the event shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. | |||||||||||||||||||||||||||||||||||||
February 18 Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible promissory notes debt discount | 126,134 | 126,134 | $ 2,810 | |||||||||||||||||||||||||||||||||||
Convertible promissory notes net | 0 | 0 | ||||||||||||||||||||||||||||||||||||
Debt instrument face amount | $ 500,000 | $ 500,000 | 430,000 | $ 70,000 | $ 430,000 | |||||||||||||||||||||||||||||||||
Debt instrument maturity date | Feb. 18, 2023 | |||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | 10.00% | 10.00% | |||||||||||||||||||||||||||||||||||
Debt instrument conversion price description | The Feb 18 Note is convertible into shares of the Company’s common stock at conversion prices ranging from the a) the lesser of $0.03 per share of common stock (subject to adjustment for stock splits, dividends, combinations and other similar transactions) or b) fifty percent (50%) of the lowest trade price recorded since the original effective date, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. If the Borrower fails to deliver shares in accordance with-in the time frame of three (3) business days, the Lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to the Borrower. In addition, for each conversion, in the event shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. | The Feb 18 Note is convertible into shares of the Company’s common stock at conversion prices ranging from the a) the lesser of $0.03 per share of common stock (subject to adjustment for stock splits, dividends, combinations and other similar transactions) or b) fifty percent (50%) of the lowest trade price recorded since the original effective date, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. If the Borrower fails to deliver shares in accordance with-in the time frame of three (3) business days, the Lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to the Borrower. In addition, for each conversion, in the event shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. | ||||||||||||||||||||||||||||||||||||
Shares of common stock upon conversion of principal amount | $ 500,000 | |||||||||||||||||||||||||||||||||||||
Accrued interest | 98,566 | |||||||||||||||||||||||||||||||||||||
Remaining balance of note | 430,000 | |||||||||||||||||||||||||||||||||||||
February 18 Note [Member] | Convertible Notes Payable [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Debt instrument face amount | $ 75,000 | 355,000 | ||||||||||||||||||||||||||||||||||||
August 2019 Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible promissory notes debt discount | $ 2,000 | $ 2,000 | ||||||||||||||||||||||||||||||||||||
Convertible promissory notes net | $ 0 | 0 | ||||||||||||||||||||||||||||||||||||
Debt instrument face amount | $ 53,500 | $ 53,500 | ||||||||||||||||||||||||||||||||||||
Debt instrument maturity date | Feb. 14, 2021 | |||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | 10.00% | ||||||||||||||||||||||||||||||||||||
Debt instrument conversion price description | The August 2019 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest one (1) day trading price or lowest bid price during the fifteen (15) trading days prior to the conversion date. The parties agree that if shares of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the August 2019 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the August 2019 Note. The fair value of the August 2019 Notes has been determined by using the Binomial lattice formula from the effective date of the notes. | |||||||||||||||||||||||||||||||||||||
Shares of common stock upon conversion of principal amount | $ 40,676 | 12,824 | ||||||||||||||||||||||||||||||||||||
Accrued interest | $ 5,564 | |||||||||||||||||||||||||||||||||||||
Received additional amount | $ 51,500 | |||||||||||||||||||||||||||||||||||||
Issuance of common shares for converted promissory notes and accrued interest, shares | 21,000,000 | 908,119 | ||||||||||||||||||||||||||||||||||||
Other fees | $ 3,000 | $ 1,000 | ||||||||||||||||||||||||||||||||||||
February Two Thousand Twenty Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible promissory notes debt discount | $ 2,000 | $ 2,000 | 6,578 | 6,578 | ||||||||||||||||||||||||||||||||||
Convertible promissory notes net | 53,500 | 53,500 | ||||||||||||||||||||||||||||||||||||
Debt instrument face amount | $ 53,500 | $ 53,500 | ||||||||||||||||||||||||||||||||||||
Debt instrument maturity date | Feb. 13, 2021 | |||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | 10.00% | ||||||||||||||||||||||||||||||||||||
Debt instrument conversion price description | The Feb 2020 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest one (1) day trading price or lowest bid price during the fifteen (15) trading days prior to the conversion date. The parties agree that if the shares of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Feb 2020 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Feb 2020 Note. The fair value of the Feb 2020 Note has been determined by using the Binomial lattice formula from the effective date of the notes. | |||||||||||||||||||||||||||||||||||||
Received additional amount | $ 51,500 | |||||||||||||||||||||||||||||||||||||
July Two Thousand Twenty Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible promissory notes debt discount | $ 3,000 | $ 3,000 | 27,153 | 27,153 | ||||||||||||||||||||||||||||||||||
Convertible promissory notes net | 0 | 0 | ||||||||||||||||||||||||||||||||||||
Debt instrument face amount | $ 53,000 | $ 53,000 | ||||||||||||||||||||||||||||||||||||
Debt instrument maturity date | Jul. 6, 2021 | |||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | 10.00% | ||||||||||||||||||||||||||||||||||||
Debt instrument conversion price description | The Jul 2020 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest average two (2) day closing bid prices during the fifteen (15) trading days prior to the conversion date. The parties agree that if delivery of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Jul 2020 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Jul 2020 Note. The fair value of the Jul 2020 Note has been determined by using the Binomial lattice formula from the effective date of the notes. | |||||||||||||||||||||||||||||||||||||
Shares of common stock upon conversion of principal amount | 53,000 | |||||||||||||||||||||||||||||||||||||
Accrued interest | $ 2,650 | |||||||||||||||||||||||||||||||||||||
Received additional amount | $ 50,000 | |||||||||||||||||||||||||||||||||||||
Issuance of common shares for converted promissory notes and accrued interest, shares | 4,062,044 | |||||||||||||||||||||||||||||||||||||
August Two Thousand Twenty Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible promissory notes debt discount | $ 3,000 | $ 3,000 | 31,219 | $ 31,219 | ||||||||||||||||||||||||||||||||||
Convertible promissory notes net | $ 0 | |||||||||||||||||||||||||||||||||||||
Debt instrument face amount | $ 53,000 | $ 53,000 | ||||||||||||||||||||||||||||||||||||
Debt instrument maturity date | Aug. 4, 2021 | |||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | 10.00% | ||||||||||||||||||||||||||||||||||||
Debt instrument conversion price description | The Aug 2020 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest average two (2) day closing bid prices during the fifteen (15) trading days prior to the conversion date. The parties agree that if delivery of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Aug 2020 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Aug 2020 Note. The fair value of the Aug 2020 Note has been determined by using the Binomial lattice formula from the effective date of the notes. | |||||||||||||||||||||||||||||||||||||
Shares of common stock upon conversion of principal amount | 53,000 | |||||||||||||||||||||||||||||||||||||
Accrued interest | $ 2,650 | |||||||||||||||||||||||||||||||||||||
Received additional amount | $ 50,000 | |||||||||||||||||||||||||||||||||||||
Issuance of common shares for converted promissory notes and accrued interest, shares | 868,175 | |||||||||||||||||||||||||||||||||||||
Unsecured Convertible Promissory Note One [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible promissory notes debt discount | $ 2,000 | 13,338 | $ 13,338 | |||||||||||||||||||||||||||||||||||
Convertible promissory notes net | 53,500 | 53,500 | ||||||||||||||||||||||||||||||||||||
Debt instrument face amount | $ 53,500 | |||||||||||||||||||||||||||||||||||||
Debt instrument maturity date | Aug. 17, 2021 | |||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||
Debt instrument conversion price description | The Aug 2020 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest one (1) day trading price or lowest bid price during the fifteen (15) trading days prior to the conversion date. The parties agree that if the shares of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Aug 2020 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Aug 2020 Note. The fair value of the Aug 2020 Note has been determined by using the Binomial lattice formula from the effective date of the notes. | |||||||||||||||||||||||||||||||||||||
Received additional amount | $ 51,500 | |||||||||||||||||||||||||||||||||||||
September Two Thousand Twenty Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible promissory notes debt discount | $ 3,000 | $ 3,000 | 37,318 | 37,318 | ||||||||||||||||||||||||||||||||||
Convertible promissory notes net | 0 | 0 | ||||||||||||||||||||||||||||||||||||
Debt instrument face amount | $ 53,000 | $ 53,000 | ||||||||||||||||||||||||||||||||||||
Debt instrument maturity date | Sep. 14, 2021 | |||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | 10.00% | ||||||||||||||||||||||||||||||||||||
Debt instrument conversion price description | The Sep 2020 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest average two (2) day closing bid prices during the fifteen (15) trading days prior to the conversion date. The parties agree that if delivery of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Sep 2020 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Sep 2020 Note. The fair value of the Sep 2020 Note has been determined by using the Binomial lattice formula from the effective date of the notes. | |||||||||||||||||||||||||||||||||||||
Shares of common stock upon conversion of principal amount | 53,000 | |||||||||||||||||||||||||||||||||||||
Accrued interest | $ 2,650 | |||||||||||||||||||||||||||||||||||||
Received additional amount | $ 50,000 | |||||||||||||||||||||||||||||||||||||
Issuance of common shares for converted promissory notes and accrued interest, shares | 2,100,000 | |||||||||||||||||||||||||||||||||||||
November Two Thousand Twenty Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible promissory notes debt discount | $ 3,000 | 44,433 | $ 44,433 | |||||||||||||||||||||||||||||||||||
Convertible promissory notes net | 0 | 0 | ||||||||||||||||||||||||||||||||||||
Debt instrument face amount | $ 53,000 | |||||||||||||||||||||||||||||||||||||
Debt instrument maturity date | Nov. 2, 2021 | |||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||
Debt instrument conversion price description | The Nov 2020 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest average two (2) day closing bid prices during the fifteen (15) trading days prior to the conversion date. The parties agree that if delivery of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Nov 2020 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Nov 2020 Note. The fair value of the Nov 2020 Note has been determined by using the Binomial lattice formula from the effective date of the notes. | |||||||||||||||||||||||||||||||||||||
December Two Thousand Twenty Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible promissory notes debt discount | $ 3,000 | 3,416 | 3,416 | |||||||||||||||||||||||||||||||||||
Convertible promissory notes net | 0 | 0 | ||||||||||||||||||||||||||||||||||||
Debt instrument face amount | $ 53,000 | |||||||||||||||||||||||||||||||||||||
Debt instrument maturity date | Dec. 2, 2021 | |||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||
Debt instrument conversion price description | The Dec 2020 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest average two (2) day closing bid prices during the fifteen (15) trading days prior to the conversion date. The parties agree that if delivery of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. | |||||||||||||||||||||||||||||||||||||
Received additional amount | $ 50,000 | |||||||||||||||||||||||||||||||||||||
January Two Thousand Twenty One Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible promissory notes debt discount | $ 3,000 | 53,500 | 53,500 | |||||||||||||||||||||||||||||||||||
Convertible promissory notes net | 0 | 0 | ||||||||||||||||||||||||||||||||||||
Debt instrument face amount | $ 53,500 | |||||||||||||||||||||||||||||||||||||
Debt instrument maturity date | Jan. 4, 2021 | |||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||
Debt instrument conversion price description | The Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest average two (2) day closing bid prices during the fifteen (15) trading days prior to the conversion date. The parties agree that if delivery of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Jan 4 2021 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Jan 4 2021 Note. The fair value of the Jan 4 2021 Note has been determined by using the Binomial lattice formula from the effective date of the notes. | |||||||||||||||||||||||||||||||||||||
Received additional amount | $ 50,000 | |||||||||||||||||||||||||||||||||||||
January Two Thousand Twenty One Note One [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible promissory notes debt discount | $ 3,000 | 53,500 | 53,500 | |||||||||||||||||||||||||||||||||||
Convertible promissory notes net | $ 0 | 0 | ||||||||||||||||||||||||||||||||||||
Debt instrument face amount | $ 53,500 | |||||||||||||||||||||||||||||||||||||
Debt instrument maturity date | Jan. 14, 2021 | |||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||
Debt instrument conversion price description | The Jan 14 2021 Note may be converted into shares of the Company’s common stock at a conversion price of sixty-one (61%) percent of the lowest average two (2) day closing bid prices during the fifteen (15) trading days prior to the conversion date. The parties agree that if delivery of the common stock issuable upon conversion of these Notes are not delivered by the deadline, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the deadline that the Borrower fails to deliver such common stock. The conversion feature of the Jan 14 2021 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Jan 14 2021 Note. The fair value of the Jan 14 2021 Note has been determined by using the Binomial lattice formula from the effective date of the notes. | |||||||||||||||||||||||||||||||||||||
Received additional amount | $ 50,000 | |||||||||||||||||||||||||||||||||||||
Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Shares of common stock upon conversion of principal amount | 2,462,060 | |||||||||||||||||||||||||||||||||||||
Accrued interest | 1,023,253 | |||||||||||||||||||||||||||||||||||||
Paid off principal | 203,000 | |||||||||||||||||||||||||||||||||||||
Paid off interest | $ 52,780 | |||||||||||||||||||||||||||||||||||||
Two Zero One Five Two Zero One Eight Notes [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Remaining balance of note | 1,957,800 | |||||||||||||||||||||||||||||||||||||
Feb April 2019 Notes [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Convertible promissory notes debt discount | $ 4,000 | $ 4,000 | 21,801 | |||||||||||||||||||||||||||||||||||
Debt instrument face amount | $ 107,000 | |||||||||||||||||||||||||||||||||||||
Note bears interest rate | 1000.00% | 1000.00% | ||||||||||||||||||||||||||||||||||||
Accrued interest | 6,351 | |||||||||||||||||||||||||||||||||||||
Received additional amount | $ 103,000 | |||||||||||||||||||||||||||||||||||||
Issuance of common shares for converted promissory notes and accrued interest, shares | 34,267,881 | |||||||||||||||||||||||||||||||||||||
Other fees | 1,750 | |||||||||||||||||||||||||||||||||||||
Feb April Two Thousand Ninteen [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Shares of common stock upon conversion of principal amount | $ 72,384 | |||||||||||||||||||||||||||||||||||||
July Two Zero One Nine Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||
Shares of common stock upon conversion of principal amount | $ 53,000 | |||||||||||||||||||||||||||||||||||||
Received additional amount | $ 50,000 | |||||||||||||||||||||||||||||||||||||
Issuance of common shares for converted promissory notes and accrued interest, shares | 8,248,918 | |||||||||||||||||||||||||||||||||||||
Unsecured convertible promissory note | 53,000 | |||||||||||||||||||||||||||||||||||||
Debt discount | $ 30 | |||||||||||||||||||||||||||||||||||||
Accrued interest | $ 2,650 | |||||||||||||||||||||||||||||||||||||
Interest expense | 28,672 | |||||||||||||||||||||||||||||||||||||
August Two Zero One Nine Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | 10.00% | ||||||||||||||||||||||||||||||||||||
Shares of common stock upon conversion of principal amount | $ 40,676 | |||||||||||||||||||||||||||||||||||||
Received additional amount | $ 51,500 | |||||||||||||||||||||||||||||||||||||
Issuance of common shares for converted promissory notes and accrued interest, shares | 21,000,000 | |||||||||||||||||||||||||||||||||||||
Remaining balance of note | $ 12,824 | |||||||||||||||||||||||||||||||||||||
Interest expense | 32,305 | |||||||||||||||||||||||||||||||||||||
Other fees | 3,000 | |||||||||||||||||||||||||||||||||||||
August Two Nine Two Zero One Nine Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||
Shares of common stock upon conversion of principal amount | $ 63,000 | |||||||||||||||||||||||||||||||||||||
Received additional amount | $ 60,000 | |||||||||||||||||||||||||||||||||||||
Issuance of common shares for converted promissory notes and accrued interest, shares | 13,624,762 | |||||||||||||||||||||||||||||||||||||
Unsecured convertible promissory note | 63,000 | |||||||||||||||||||||||||||||||||||||
Debt discount | $ 3,000 | |||||||||||||||||||||||||||||||||||||
Accrued interest | $ 3,150 | |||||||||||||||||||||||||||||||||||||
Interest expense | 24,408 | |||||||||||||||||||||||||||||||||||||
Oct Two Zero One Nine Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||
Shares of common stock upon conversion of principal amount | $ 63,000 | |||||||||||||||||||||||||||||||||||||
Received additional amount | $ 60,000 | |||||||||||||||||||||||||||||||||||||
Issuance of common shares for converted promissory notes and accrued interest, shares | 28,413,462 | |||||||||||||||||||||||||||||||||||||
Unsecured convertible promissory note | 63,000 | |||||||||||||||||||||||||||||||||||||
Debt discount | $ 3,000 | |||||||||||||||||||||||||||||||||||||
Accrued interest | $ 3,150 | |||||||||||||||||||||||||||||||||||||
Interest expense | 47,336 | |||||||||||||||||||||||||||||||||||||
Nov Two Zero One Nine Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||
Shares of common stock upon conversion of principal amount | $ 58,000 | |||||||||||||||||||||||||||||||||||||
Received additional amount | $ 55,000 | |||||||||||||||||||||||||||||||||||||
Issuance of common shares for converted promissory notes and accrued interest, shares | 24,588,385 | |||||||||||||||||||||||||||||||||||||
Unsecured convertible promissory note | 58,000 | |||||||||||||||||||||||||||||||||||||
Debt discount | $ 3,000 | |||||||||||||||||||||||||||||||||||||
Accrued interest | $ 2,900 | |||||||||||||||||||||||||||||||||||||
Interest expense | 48,967 | |||||||||||||||||||||||||||||||||||||
Dec Two Zero One Nine Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||
Shares of common stock upon conversion of principal amount | $ 53,000 | |||||||||||||||||||||||||||||||||||||
Received additional amount | $ 50,000 | |||||||||||||||||||||||||||||||||||||
Issuance of common shares for converted promissory notes and accrued interest, shares | 21,118,946 | |||||||||||||||||||||||||||||||||||||
Unsecured convertible promissory note | 53,000 | |||||||||||||||||||||||||||||||||||||
Debt discount | $ 3,000 | |||||||||||||||||||||||||||||||||||||
Accrued interest | $ 2,650 | |||||||||||||||||||||||||||||||||||||
Interest expense | 51,407 | |||||||||||||||||||||||||||||||||||||
Jan 2020 Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||
Shares of common stock upon conversion of principal amount | $ 53,000 | |||||||||||||||||||||||||||||||||||||
Received additional amount | $ 50,000 | |||||||||||||||||||||||||||||||||||||
Issuance of common shares for converted promissory notes and accrued interest, shares | 12,320,494 | |||||||||||||||||||||||||||||||||||||
Unsecured convertible promissory note | 53,000 | |||||||||||||||||||||||||||||||||||||
Debt discount | $ 3,000 | |||||||||||||||||||||||||||||||||||||
Accrued interest | $ 2,650 | |||||||||||||||||||||||||||||||||||||
Interest expense | 53,000 | |||||||||||||||||||||||||||||||||||||
Feb Two Zero Two Zero Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | 10.00% | ||||||||||||||||||||||||||||||||||||
Received additional amount | $ 51,500 | |||||||||||||||||||||||||||||||||||||
Remaining balance of note | 53,500 | |||||||||||||||||||||||||||||||||||||
Unsecured convertible promissory note | 53,500 | $ 53,500 | ||||||||||||||||||||||||||||||||||||
Debt discount | $ 2,000 | $ 2,000 | ||||||||||||||||||||||||||||||||||||
Interest expense | 33,474 | |||||||||||||||||||||||||||||||||||||
Mar Two Zeo Two Zero Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||
Shares of common stock upon conversion of principal amount | $ 53,000 | |||||||||||||||||||||||||||||||||||||
Received additional amount | $ 50,000 | |||||||||||||||||||||||||||||||||||||
Issuance of common shares for converted promissory notes and accrued interest, shares | 7,520,270 | |||||||||||||||||||||||||||||||||||||
Unsecured convertible promissory note | 53,000 | |||||||||||||||||||||||||||||||||||||
Debt discount | $ 3,000 | |||||||||||||||||||||||||||||||||||||
Accrued interest | $ 2,650 | |||||||||||||||||||||||||||||||||||||
Interest expense | 53,000 | |||||||||||||||||||||||||||||||||||||
Apr Two Zero Two Zero Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||
Shares of common stock upon conversion of principal amount | $ 53,000 | |||||||||||||||||||||||||||||||||||||
Received additional amount | $ 50,000 | |||||||||||||||||||||||||||||||||||||
Issuance of common shares for converted promissory notes and accrued interest, shares | 12,616,691 | |||||||||||||||||||||||||||||||||||||
Unsecured convertible promissory note | 53,000 | |||||||||||||||||||||||||||||||||||||
Debt discount | $ 3,000 | |||||||||||||||||||||||||||||||||||||
Accrued interest | $ 2,650 | |||||||||||||||||||||||||||||||||||||
Interest expense | 53,000 | |||||||||||||||||||||||||||||||||||||
Jun Two Zero Two Zero Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||
Shares of common stock upon conversion of principal amount | $ 53,000 | |||||||||||||||||||||||||||||||||||||
Issuance of common shares for converted promissory notes and accrued interest, shares | 7,623,288 | |||||||||||||||||||||||||||||||||||||
Unsecured convertible promissory note | $ 53,000 | |||||||||||||||||||||||||||||||||||||
Debt discount | $ 3,000 | |||||||||||||||||||||||||||||||||||||
Accrued interest | $ 2,650 | |||||||||||||||||||||||||||||||||||||
Interest expense | 53,000 | |||||||||||||||||||||||||||||||||||||
Ju Two Zero Two Zero Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | 10.00% | ||||||||||||||||||||||||||||||||||||
Received additional amount | $ 50,000 | |||||||||||||||||||||||||||||||||||||
Remaining balance of note | 53,000 | |||||||||||||||||||||||||||||||||||||
Unsecured convertible promissory note | 53,000 | $ 53,000 | ||||||||||||||||||||||||||||||||||||
Debt discount | $ 3,000 | $ 3,000 | ||||||||||||||||||||||||||||||||||||
Interest expense | 25,847 | |||||||||||||||||||||||||||||||||||||
Aug Two Zero Two Zero Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | 10.00% | ||||||||||||||||||||||||||||||||||||
Received additional amount | $ 50,000 | |||||||||||||||||||||||||||||||||||||
Remaining balance of note | 53,000 | |||||||||||||||||||||||||||||||||||||
Unsecured convertible promissory note | 53,000 | $ 53,000 | ||||||||||||||||||||||||||||||||||||
Debt discount | $ 3,000 | $ 3,000 | ||||||||||||||||||||||||||||||||||||
Interest expense | 21,781 | |||||||||||||||||||||||||||||||||||||
Sep Two Zero Two Zero Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | 10.00% | ||||||||||||||||||||||||||||||||||||
Received additional amount | $ 50,000 | |||||||||||||||||||||||||||||||||||||
Remaining balance of note | 53,000 | |||||||||||||||||||||||||||||||||||||
Unsecured convertible promissory note | 53,000 | $ 53,000 | ||||||||||||||||||||||||||||||||||||
Debt discount | $ 3,000 | $ 3,000 | ||||||||||||||||||||||||||||||||||||
Interest expense | 15,682 | |||||||||||||||||||||||||||||||||||||
Nov 2020 Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Note bears interest rate | 1000.00% | |||||||||||||||||||||||||||||||||||||
Received additional amount | $ 50,000 | |||||||||||||||||||||||||||||||||||||
Remaining balance of note | 53,000 | |||||||||||||||||||||||||||||||||||||
Unsecured convertible promissory note | 53,000 | |||||||||||||||||||||||||||||||||||||
Debt discount | $ 3,000 | |||||||||||||||||||||||||||||||||||||
Interest expense | 8,567 | |||||||||||||||||||||||||||||||||||||
Dec 2020 Note [Member] | ||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||
Note bears interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||
Received additional amount | $ 50,000 | |||||||||||||||||||||||||||||||||||||
Remaining balance of note | $ 43,000 | |||||||||||||||||||||||||||||||||||||
Unsecured convertible promissory note | 53,000 | |||||||||||||||||||||||||||||||||||||
Debt discount | $ 3,000 |
SCHEDULE OF DERIVATIVE LIABILIT
SCHEDULE OF DERIVATIVE LIABILITIES VALUATION ASSUMPTIONS (Details) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
Measurement Input, Risk Free Interest Rate [Member] | ||
Derivative [Line Items] | ||
Derivative liability measurement input | 0.05 | |
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | ||
Derivative [Line Items] | ||
Derivative liability measurement input | 0.0008 | |
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | ||
Derivative [Line Items] | ||
Derivative liability measurement input | 0.0017 | |
Measurement Input, Price Volatility [Member] | Minimum [Member] | ||
Derivative [Line Items] | ||
Derivative liability measurement input | 63 | 1.640 |
Measurement Input, Price Volatility [Member] | Maximum [Member] | ||
Derivative [Line Items] | ||
Derivative liability measurement input | 65 | 2.470 |
Weighted Average Expected Option Life [Member] | Minimum [Member] | ||
Derivative [Line Items] | ||
Derivative liability measurement input, period | 6 months | 6 months |
Weighted Average Expected Option Life [Member] | Maximum [Member] | ||
Derivative [Line Items] | ||
Derivative liability measurement input, period | 1 year | 5 months |
Measurement Input, Expected Dividend Rate [Member] | ||
Derivative [Line Items] | ||
Derivative liability measurement input | 0 | 0 |
DERIVATIVE LIABILITIES (Details
DERIVATIVE LIABILITIES (Details Narrative) - USD ($) | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2021 | Dec. 31, 2020 | Mar. 26, 2021 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |||
Fair value of the conversion feature | $ 180,004 | $ 632,143 | |
Debt instrument face amount | 184,124 | 738,850 | |
Accrued interest | 20,851 | 101,884 | |
Other fees | 1,000 | 4,750 | |
Fair value of the derivatives issued | 638,936 | 632,144 | $ 178,464,388 |
Loss on the change in derivatives | 30,039,479 | 139,038,754 | |
Fair value of the derivative liability | $ 73,395 | $ 148,590,100 |
RELATED PARTY TRANSACTION (Deta
RELATED PARTY TRANSACTION (Details Narrative) - $ / shares | Apr. 14, 2021 | Jan. 14, 2021 | Dec. 31, 2020 | Jun. 30, 2021 | Dec. 31, 2019 | Oct. 28, 2019 |
Related Party Transaction [Line Items] | ||||||
Preferred stock, shares outstanding | 0 | 0 | ||||
Preferred stock, shares authorized | 10,000,000 | 10,000,000 | 10,000,000 | |||
Preferred stock, shares issued | 0 | 0 | ||||
Preferred stock par value (in Dollars per share) | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||
Series B Preferred Stock [Member] | ||||||
Related Party Transaction [Line Items] | ||||||
Preferred stock, shares outstanding | 0 | |||||
Purchase price | $ 0.10 | |||||
Preferred stock, shares authorized | 1,000 | |||||
Preferred stock, voting rights | the Board of Directors adopted a certificate of designation establishing the rights, preferences, privileges and other terms of 1,000 Series B Preferred Stock, par value $0.0001 per share, providing for supermajority voting rights to holders of the Series B Preferred Stock. | |||||
Series B Preferred Stock [Member] | Mr David Lee [Member] | ||||||
Related Party Transaction [Line Items] | ||||||
Shares issued during the period for service | 1,000 | |||||
Preferred stock, shares outstanding | 0 | |||||
Purchase price | $ 0.10 | |||||
Preferred stock, shares authorized | 1,000 | |||||
Series D Preferred Stock [Member] | ||||||
Related Party Transaction [Line Items] | ||||||
Preferred stock, shares outstanding | 0 | |||||
Series D Preferred Stock [Member] | Mr David Lee [Member] | ||||||
Related Party Transaction [Line Items] | ||||||
Shares issued during the period for service | 1,000 | |||||
Purchase price | $ 0.10 | |||||
Preferred stock, shares authorized | 1,000 | |||||
Series A Preferred Stock [Member] | ||||||
Related Party Transaction [Line Items] | ||||||
Preferred stock, shares outstanding | 0 | |||||
Preferred stock, shares issued | 1,000 | |||||
Preferred stock par value (in Dollars per share) | $ 20 | |||||
Preferred stock, voting rights | The Series A Preferred Stock had a fifty-one (51%) voting right only and was redeemed at par value on December 12, 2019 |
SCHEDULE OF WARRANTS ACITIVITY
SCHEDULE OF WARRANTS ACITIVITY (Details) | 6 Months Ended |
Jun. 30, 2021$ / sharesshares | |
Securities Purchase Agreement | |
Number of Warrants, Outstanding as of the beginning of the periods | shares | |
Weighted average exercise price, Outstanding as of the beginning of the periods | $ / shares | |
Number of Warrants, Issued | shares | 315,291,668 |
Weighted average exercise price, Issued | $ / shares | $ 0.048 |
Number of Warrants, Purchased | shares | 61,333,334 |
Weighted average exercise price, Purchased | $ / shares | |
Number of Warrants, Expired | shares | |
Weighted average exercise price, Expired | $ / shares | |
Number of Warrants, Outstanding as of the end of the periods | shares | 253,958,334 |
Weighted average exercise price, Outstanding as of the end of the periods | $ / shares | $ 0.048 |
Number of Warrants, Exercisable as of the end of the periods | shares | 253,958,334 |
Weighted average exercise price, Exercisable as of the end of the periods | $ / shares | $ 0.048 |
SCHEDULE OF WARRANTS OUTSTANDIN
SCHEDULE OF WARRANTS OUTSTANDING (Details) - $ / shares | Jun. 30, 2021 | Dec. 31, 2020 |
Class of Warrant or Right [Line Items] | ||
Exercisable Price | $ 0.048 | |
Stock Warrants Outstanding | 253,958,334 | |
Stock Warrants Exercisable | 253,958,334 | |
Warrant One [Member] | ||
Class of Warrant or Right [Line Items] | ||
Exercisable Price | $ 0.0001 | |
Stock Warrants Outstanding | 30,000,000 | |
Stock Warrants Exercisable | 30,000,000 | |
Weighted Average Remaining Contractua Life (years) | 4 years 9 months 7 days | |
Warrant Two [Member] | ||
Class of Warrant or Right [Line Items] | ||
Exercisable Price | $ 0.04 | |
Stock Warrants Outstanding | 125,000,000 | |
Stock Warrants Exercisable | 125,000,000 | |
Weighted Average Remaining Contractua Life (years) | 4 years 9 months 7 days | |
Warrant Three [Member] | ||
Class of Warrant or Right [Line Items] | ||
Exercisable Price | $ 0.05 | |
Stock Warrants Outstanding | 9,375,000 | |
Stock Warrants Exercisable | 9,375,000 | |
Weighted Average Remaining Contractua Life (years) | 4 years 9 months 3 days | |
Warrant Four [Member] | ||
Class of Warrant or Right [Line Items] | ||
Exercisable Price | $ 0.06 | |
Stock Warrants Outstanding | 83,333,334 | |
Stock Warrants Exercisable | 83,333,334 | |
Weighted Average Remaining Contractua Life (years) | 5 years 29 days | |
Warrant Five [Member] | ||
Class of Warrant or Right [Line Items] | ||
Exercisable Price | $ 0.075 | |
Stock Warrants Outstanding | 6,250,000 | |
Stock Warrants Exercisable | 6,250,000 | |
Weighted Average Remaining Contractua Life (years) | 5 years 29 days |
SECURITIES PURCHASE AGREEMENT_2
SECURITIES PURCHASE AGREEMENT (Details Narrative) - USD ($) | Apr. 04, 2021 | Jan. 27, 2021 | Jun. 30, 2021 | Jun. 30, 2020 |
Pre-funded warrants to be purchased | 30,000,000 | |||
Proceeds from common stock | $ 8,781,700 | |||
Common Stock [Member] | ||||
Shares issued during the period private placement | 178,333,334 | |||
Securities Purchase Agreement [Member] | Warrant [Member] | ||||
Pre-funded warrants to be purchased | 9,375,000 | 6,250,000 | ||
Exercise price | $ 0.05 | $ 0.075 | ||
Termination date | Apr. 4, 2026 | Jul. 27, 2026 | ||
Securities Purchase Agreement [Member] | Investor [Member] | ||||
Shares issued during the period private placement | 65,000,000 | 52,000,000 | 52,000,000 | |
Exercise price | $ 0.04 | $ 0.06 | $ 0.06 | |
Purchase price description | In addition, the combined purchase price of $0.04 per one (1) share of common stock and associated warrant had a purchase price of $0.0399 per one (1) pre-funded | In addition, the combined purchase price of $0.06 per one (1) share of common stock and associated warrant had a purchase price of $0.0599 per one (1) pre-funded | ||
Proceeds from warrant | $ 4,372,350 | $ 4,409,350 | ||
Proceeds from common stock | 4,369,350 | 4,406,217 | ||
Common stock prefunded amount | $ 3,000 | $ 3,133 | ||
Securities Purchase Agreement [Member] | Investor [Member] | Common Stock [Member] | ||||
Exercise price | $ 0.04 | $ 0.06 | ||
Proceeds from common stock | $ 5,000,000 | $ 5,000,000 | ||
Securities Purchase Agreement [Member] | Investor [Member] | Common Stock [Member] | Maximum [Member] | ||||
Shares issued during the period private placement | 60,000,000 | 31,333,334 | 31,333,334 | |
Securities Purchase Agreement [Member] | Investor [Member] | Warrant [Member] | ||||
Pre-funded warrants to be purchased | 5,000,000 | 5,000,000 | ||
Exercise price | $ 0.0399 | $ 0.0599 | ||
Proceeds from warrant | $ 4,994,000 | $ 4,996,866 | ||
Securities Purchase Agreement [Member] | Investor [Member] | Warrant [Member] | Maximum [Member] | ||||
Pre-funded warrants to be purchased | 125,000,000 | 83,333,334 | 83,333,334 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | ||
Monthly rent payment | $ 550 | $ 550 |
SUBSEQUENT EVENT (Details Narra
SUBSEQUENT EVENT (Details Narrative) - USD ($) | Jul. 20, 2021 | Feb. 05, 2021 | Feb. 04, 2021 | Jan. 15, 2021 | Jan. 07, 2021 | Feb. 28, 2021 | Jan. 31, 2021 | Jan. 27, 2021 | Jun. 30, 2021 | Jan. 14, 2021 | Jan. 13, 2021 | Jan. 04, 2021 | Dec. 31, 2020 |
Subsequent Event [Line Items] | |||||||||||||
Exercise price of warrants | $ 0.048 | ||||||||||||
Principal amount | $ 184,124 | $ 738,850 | |||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 30,000,000 | ||||||||||||
Subsequent Event [Member] | |||||||||||||
Subsequent Event [Line Items] | |||||||||||||
Unsecured convertible note, percentage | 10.00% | 10.00% | |||||||||||
Principal amount | $ 1,282,400 | $ 5,300,000 | $ 1,230,000 | $ 5,300,000 | $ 5,350,000 | $ 5,350,000 | |||||||
Conversion of common stock, description | The Feb 2021 Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of 61% of the average of the two lowest (2) day trading prices for common stock during the fifteen (15) trading day period prior to the conversion date. | The Jan 2021 Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of 61% of the average of the two lowest (2) day trading prices for common stock during the fifteen (15) trading day period prior to the conversion date | |||||||||||
Common stock upon conversion issued, shares (in Shares) | 908,118 | 868,175 | 14,025,851 | 4,062,044 | |||||||||
Accrued interest | $ 556,400 | $ 265,000 | $ 733,600 | $ 265,000 | |||||||||
Fund amount received | $ 5,000,000 | ||||||||||||
Price per share (in Dollars per share) | $ 0.0599 | ||||||||||||
Other fees | $ 100,000 | ||||||||||||
Subsequent Event [Member] | Private Placement [Member] | |||||||||||||
Subsequent Event [Line Items] | |||||||||||||
Aggregate of shares (in Shares) | 52,000,000 | ||||||||||||
Common Stock [Member] | |||||||||||||
Subsequent Event [Line Items] | |||||||||||||
Number of share issued | 178,333,334 | ||||||||||||
Issuance of preferred shares for services (in Shares) | 1,000,000 | ||||||||||||
Common Stock [Member] | Subsequent Event [Member] | |||||||||||||
Subsequent Event [Line Items] | |||||||||||||
Number of share issued | 30,000,000 | ||||||||||||
Exercise price of warrants | $ 0.0001 | ||||||||||||
Aggregate of shares (in Shares) | 83,333,334 | ||||||||||||
Gross proceeds | $ 500,000,000 | ||||||||||||
Issuance of preferred shares for services (in Shares) | 1,000,000 | ||||||||||||
Warrant [Member] | Subsequent Event [Member] | |||||||||||||
Subsequent Event [Line Items] | |||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 31,333,334 | ||||||||||||
Price per share (in Dollars per share) | $ 0.06 |
ORGANIZATION AND LINE OF BUSI_2
ORGANIZATION AND LINE OF BUSINESS (Details Narrative) | 12 Months Ended |
Dec. 31, 2020USD ($) | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Net loss | $ 140,544,660 |
Change in derivative | 139,038,754 |
Used cash in operations | 647,298 |
Working capital deficiency | 150,532,859 |
Stockholders deficit | $ 151,914,888 |
SCHEDULE OF RECONCILIATION OF_2
SCHEDULE OF RECONCILIATION OF DERIVATIVE LIABILITY (Details) - USD ($) | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Accounting Policies [Abstract] | |||
Beginning Balance | $ 148,590,100 | $ 8,919,202 | $ 14,032,942 |
Fair value of derivative liabilities issued | 180,004 | 632,144 | 663,608 |
Loss on change in derivative liability | (30,039,478) | 139,038,754 | (5,777,348) |
Ending Balance | $ 73,395 | $ 148,590,100 | $ 8,919,202 |
SCHEDULE OF MATURITIES OF LONG-
SCHEDULE OF MATURITIES OF LONG-TERM DEBT, NET OF DEBT DISCOUNT (Details) | Dec. 31, 2008USD ($) |
Debt Disclosure [Abstract] | |
2021 | $ 1,289,824 |
2022 | 473,560 |
2023 | 900,800 |
2024 | 25,000 |
2025 | 75,000 |
Total long-term debt | $ 2,764,184 |
SCHEDULE OF COMPONENTS OF INCOM
SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Income Tax Disclosure [Abstract] | ||
Book Income (Loss) | $ (29,514,380) | $ 1,236,710 |
Non-deductible expenses | 29,381,500 | (1,013,080) |
Valuation Allowance | 132,880 | (223,630) |
Income tax expense |
SCHEDULE OF DEFERRED TAX ASSETS
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($) | Dec. 31, 2020 | Dec. 31, 2019 |
Deferred tax assets: | ||
NOL carryover | $ (2,076,950) | $ (1,947,750) |
R & D credit | 166,875 | 142,385 |
Depreciation | 10,735 | 10,735 |
Less Valuation Allowance | 1,899,340 | 1,794,630 |
Net deferred tax asset |
INCOME TAXES (Details Narrative
INCOME TAXES (Details Narrative) - USD ($) | 1 Months Ended | 12 Months Ended |
Dec. 22, 2017 | Dec. 31, 2020 | |
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | ||
U.S. statutory federal income tax rate | 30.00% | |
Operating loss carry-forwards (in Dollars) | $ 989,000,000 | |
Maximum [Member] | ||
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | ||
U.S. statutory federal income tax rate | 35.00% | |
Minimum [Member] | ||
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | ||
U.S. statutory federal income tax rate | 21.00% |